1
|
Kowald L, Roedig J, Karlowitz R, Wagner K, Smith S, Juretschke T, Beli P, Müller S, van Wijk SJL. USP22 regulates APL differentiation via PML-RARα stabilization and IFN repression. Cell Death Discov 2024; 10:128. [PMID: 38467608 PMCID: PMC10928094 DOI: 10.1038/s41420-024-01894-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2023] [Revised: 02/23/2024] [Accepted: 02/27/2024] [Indexed: 03/13/2024] Open
Abstract
Ubiquitin-specific peptidase 22 (USP22) is a deubiquitinating enzyme (DUB) that underlies tumorigenicity, proliferation, cell death and differentiation through deubiquitination of histone and non-histone targets. Ubiquitination determines stability, localization and functions of cell fate proteins and controls cell-protective signaling pathways to surveil cell cycle progression. In a variety of carcinomas, lymphomas and leukemias, ubiquitination regulates the tumor-suppressive functions of the promyelocytic leukemia protein (PML), but PML-specific DUBs, DUB-controlled PML ubiquitin sites and the functional consequences of PML (de)ubiquitination remain unclear. Here, we identify USP22 as regulator of PML and the oncogenic acute promyelocytic leukemia (APL) fusion PML-RARα protein stability and identify a destabilizing role of PML residue K394. Additionally, loss of USP22 upregulates interferon (IFN) and IFN-stimulated gene (ISG) expression in APL and induces PML-RARα stabilization and a potentiation of the cell-autonomous sensitivity towards all-trans retinoic acid (ATRA)-mediated differentiation. Our findings imply USP22-dependent surveillance of PML-RARα stability and IFN signaling as important regulator of APL pathogenesis, with implications for viral mimicry, differentiation and cell fate regulation in other leukemia subtypes.
Collapse
Affiliation(s)
- Lisa Kowald
- Institute for Experimental Pediatric Hematology and Oncology, Medical Faculty, Goethe-University Frankfurt, Komturstrasse 3a, 60528, Frankfurt am Main, Germany
| | - Jens Roedig
- Institute for Experimental Pediatric Hematology and Oncology, Medical Faculty, Goethe-University Frankfurt, Komturstrasse 3a, 60528, Frankfurt am Main, Germany
| | - Rebekka Karlowitz
- Institute for Experimental Pediatric Hematology and Oncology, Medical Faculty, Goethe-University Frankfurt, Komturstrasse 3a, 60528, Frankfurt am Main, Germany
| | - Kristina Wagner
- Institute of Biochemistry II (IBCII), Medical Faculty, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - Sonja Smith
- Institute for Experimental Pediatric Hematology and Oncology, Medical Faculty, Goethe-University Frankfurt, Komturstrasse 3a, 60528, Frankfurt am Main, Germany
| | - Thomas Juretschke
- Institute of Molecular Biology (IMB), Ackermannweg 4, 55128, Mainz, Germany
| | - Petra Beli
- Institute of Molecular Biology (IMB), Ackermannweg 4, 55128, Mainz, Germany
| | - Stefan Müller
- Institute of Biochemistry II (IBCII), Medical Faculty, Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany
| | - Sjoerd J L van Wijk
- Institute for Experimental Pediatric Hematology and Oncology, Medical Faculty, Goethe-University Frankfurt, Komturstrasse 3a, 60528, Frankfurt am Main, Germany.
- German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, Frankfurt am Main, Germany.
- German Cancer Research Center (DKFZ), Heidelberg, Germany.
- University Cancer Centre Frankfurt (UCT), University Hospital Frankfurt, Goethe-University Frankfurt, Frankfurt, Germany.
| |
Collapse
|
2
|
Dönig J, Mende H, Davila Gallesio J, Wagner K, Hotz P, Schunck K, Piller T, Hölper S, Uhan S, Kaulich M, Wirth M, Keller U, Tascher G, Bohnsack KE, Müller S. Characterization of nucleolar SUMO isopeptidases unveils a general p53-independent checkpoint of impaired ribosome biogenesis. Nat Commun 2023; 14:8121. [PMID: 38065954 PMCID: PMC10709353 DOI: 10.1038/s41467-023-43751-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2022] [Accepted: 11/10/2023] [Indexed: 12/18/2023] Open
Abstract
Ribosome biogenesis is a multi-step process, in which a network of trans-acting factors ensures the coordinated assembly of pre-ribosomal particles in order to generate functional ribosomes. Ribosome biogenesis is tightly coordinated with cell proliferation and its perturbation activates a p53-dependent cell-cycle checkpoint. How p53-independent signalling networks connect impaired ribosome biogenesis to the cell-cycle machinery has remained largely enigmatic. We demonstrate that inactivation of the nucleolar SUMO isopeptidases SENP3 and SENP5 disturbs distinct steps of 40S and 60S ribosomal subunit assembly pathways, thereby triggering the canonical p53-dependent impaired ribosome biogenesis checkpoint. However, inactivation of SENP3 or SENP5 also induces a p53-independent checkpoint that converges on the specific downregulation of the key cell-cycle regulator CDK6. We further reveal that impaired ribosome biogenesis generally triggers the downregulation of CDK6, independent of the cellular p53 status. Altogether, these data define the role of SUMO signalling in ribosome biogenesis and unveil a p53-independent checkpoint of impaired ribosome biogenesis.
Collapse
Affiliation(s)
- Judith Dönig
- Institute of Biochemistry II, Goethe University Frankfurt, Medical Faculty, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany
| | - Hannah Mende
- Institute of Biochemistry II, Goethe University Frankfurt, Medical Faculty, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany
| | - Jimena Davila Gallesio
- Department of Molecular Biology, University Medical Centre Göttingen, Humboldtallee 23, 37073, Göttingen, Germany
| | - Kristina Wagner
- Institute of Biochemistry II, Goethe University Frankfurt, Medical Faculty, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany
| | - Paul Hotz
- Institute of Biochemistry II, Goethe University Frankfurt, Medical Faculty, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany
| | - Kathrin Schunck
- Institute of Biochemistry II, Goethe University Frankfurt, Medical Faculty, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany
- PharmBioTec gGmbH, Schiffweiler, Germany
| | - Tanja Piller
- Institute of Biochemistry II, Goethe University Frankfurt, Medical Faculty, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany
- Sanofi AG, Frankfurt, Germany
| | - Soraya Hölper
- Institute of Biochemistry II, Goethe University Frankfurt, Medical Faculty, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany
- Sanofi AG, Frankfurt, Germany
| | - Sara Uhan
- Department of Hematology, Oncology and Cancer Immunology (Campus Benjamin Franklin), Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany
- German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
- Max Delbrück Center, Robert-Rössle-Str. 10, 13125, Berlin, Germany
| | - Manuel Kaulich
- Institute of Biochemistry II, Goethe University Frankfurt, Medical Faculty, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany
| | - Matthias Wirth
- Department of Hematology, Oncology and Cancer Immunology (Campus Benjamin Franklin), Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany
- German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
- Max Delbrück Center, Robert-Rössle-Str. 10, 13125, Berlin, Germany
- Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Germany
| | - Ulrich Keller
- Department of Hematology, Oncology and Cancer Immunology (Campus Benjamin Franklin), Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203, Berlin, Germany
- German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
- Max Delbrück Center, Robert-Rössle-Str. 10, 13125, Berlin, Germany
| | - Georg Tascher
- Institute of Biochemistry II, Goethe University Frankfurt, Medical Faculty, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany
| | - Katherine E Bohnsack
- Department of Molecular Biology, University Medical Centre Göttingen, Humboldtallee 23, 37073, Göttingen, Germany
| | - Stefan Müller
- Institute of Biochemistry II, Goethe University Frankfurt, Medical Faculty, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany.
- German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.
| |
Collapse
|
3
|
Senter J, Wagner K, Gabryszewski SJ, Wolfset N, Reid W, Sun D. Severe Pneumonia in a Previously Healthy Infant. Clin Pediatr (Phila) 2023; 62:1595-1598. [PMID: 36964682 DOI: 10.1177/00099228231163381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/26/2023]
Affiliation(s)
- James Senter
- Department of General Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Kristina Wagner
- Department of General Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Stanislaw J Gabryszewski
- Division of Allergy and Immunology, Department of General Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Nicole Wolfset
- Division of Allergy and Immunology, Department of General Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Whitney Reid
- Division of Allergy and Immunology, Department of General Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Di Sun
- Division of Allergy and Immunology, Department of General Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| |
Collapse
|
4
|
Zhang L, Wirth M, Patra U, Stroh J, Isaakidis K, Rieger L, Kossatz S, Milanovic M, Zang C, Demel U, Keiten‐Schmitz J, Wagner K, Steiger K, Rad R, Bassermann F, Müller S, Keller U, Schick M. Actionable loss of SLF2 drives B-cell lymphomagenesis and impairs the DNA damage response. EMBO Mol Med 2023; 15:e16431. [PMID: 37485814 PMCID: PMC10493575 DOI: 10.15252/emmm.202216431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Revised: 07/02/2023] [Accepted: 07/06/2023] [Indexed: 07/25/2023] Open
Abstract
The DNA damage response (DDR) acts as a barrier to malignant transformation and is often impaired during tumorigenesis. Exploiting the impaired DDR can be a promising therapeutic strategy; however, the mechanisms of inactivation and corresponding biomarkers are incompletely understood. Starting from an unbiased screening approach, we identified the SMC5-SMC6 Complex Localization Factor 2 (SLF2) as a regulator of the DDR and biomarker for a B-cell lymphoma (BCL) patient subgroup with an adverse prognosis. SLF2-deficiency leads to loss of DDR factors including Claspin (CLSPN) and consequently impairs CHK1 activation. In line with this mechanism, genetic deletion of Slf2 drives lymphomagenesis in vivo. Tumor cells lacking SLF2 are characterized by a high level of DNA damage, which leads to alterations of the post-translational SUMOylation pathway as a safeguard. The resulting co-dependency confers synthetic lethality to a clinically applicable SUMOylation inhibitor (SUMOi), and inhibitors of the DDR pathway act highly synergistic with SUMOi. Together, our results identify SLF2 as a DDR regulator and reveal co-targeting of the DDR and SUMOylation as a promising strategy for treating aggressive lymphoma.
Collapse
Affiliation(s)
- Le Zhang
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin FranklinCharité ‐ Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)HeidelbergGermany
| | - Matthias Wirth
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin FranklinCharité ‐ Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)HeidelbergGermany
- Max‐Delbrück‐Center for Molecular MedicineBerlinGermany
| | - Upayan Patra
- Institute of Biochemistry IIGoethe University Frankfurt, Medical SchoolFrankfurtGermany
| | - Jacob Stroh
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)HeidelbergGermany
- Department of Medicine III, Klinikum rechts der IsarTechnical University of MunichMunichGermany
| | - Konstandina Isaakidis
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin FranklinCharité ‐ Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)HeidelbergGermany
- Max‐Delbrück‐Center for Molecular MedicineBerlinGermany
| | - Leonie Rieger
- Department of Medicine III, Klinikum rechts der IsarTechnical University of MunichMunichGermany
- Center for Translational Cancer Research (TranslaTUM)Technische Universität MünchenMunichGermany
| | - Susanne Kossatz
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)HeidelbergGermany
- Center for Translational Cancer Research (TranslaTUM)Technische Universität MünchenMunichGermany
- Nuclear Medicine, Klinikum rechts der IsarTechnical University of MunichMunichGermany
| | - Maja Milanovic
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin FranklinCharité ‐ Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)HeidelbergGermany
- Max‐Delbrück‐Center for Molecular MedicineBerlinGermany
| | - Chuanbing Zang
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin FranklinCharité ‐ Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)HeidelbergGermany
- Max‐Delbrück‐Center for Molecular MedicineBerlinGermany
| | - Uta Demel
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin FranklinCharité ‐ Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)HeidelbergGermany
- Max‐Delbrück‐Center for Molecular MedicineBerlinGermany
- Clinician Scientist ProgramBerlin Institute of Health (BIH)BerlinGermany
| | - Jan Keiten‐Schmitz
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)HeidelbergGermany
- Institute of Biochemistry IIGoethe University Frankfurt, Medical SchoolFrankfurtGermany
| | - Kristina Wagner
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)HeidelbergGermany
- Institute of Biochemistry IIGoethe University Frankfurt, Medical SchoolFrankfurtGermany
| | - Katja Steiger
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)HeidelbergGermany
- Comparative Experimental Pathology, Institute of PathologyTechnical University of MunichMunichGermany
| | - Roland Rad
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)HeidelbergGermany
- Center for Translational Cancer Research (TranslaTUM)Technische Universität MünchenMunichGermany
- Institute of Molecular Oncology and Functional Genomics, TUM School of MedicineTechnische Universität MünchenMunichGermany
| | - Florian Bassermann
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)HeidelbergGermany
- Department of Medicine III, Klinikum rechts der IsarTechnical University of MunichMunichGermany
- Center for Translational Cancer Research (TranslaTUM)Technische Universität MünchenMunichGermany
| | - Stefan Müller
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)HeidelbergGermany
- Institute of Biochemistry IIGoethe University Frankfurt, Medical SchoolFrankfurtGermany
| | - Ulrich Keller
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin FranklinCharité ‐ Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)HeidelbergGermany
- Max‐Delbrück‐Center for Molecular MedicineBerlinGermany
| | - Markus Schick
- Department of Hematology, Oncology and Cancer Immunology, Campus Benjamin FranklinCharité ‐ Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu BerlinBerlinGermany
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ)HeidelbergGermany
- Max‐Delbrück‐Center for Molecular MedicineBerlinGermany
| |
Collapse
|
5
|
Kotch C, Wagner K, Broad JH, Dombi E, Minturn JE, Phillips P, Smith K, Li Y, Jacobs IN, Elden LM, Fisher MJ, Belasco J. Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study. Cancers (Basel) 2023; 15:cancers15092621. [PMID: 37174087 PMCID: PMC10177272 DOI: 10.3390/cancers15092621] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Revised: 05/01/2023] [Accepted: 05/03/2023] [Indexed: 05/15/2023] Open
Abstract
Limited therapies exist for neurofibromatosis type 1 (NF1)-associated plexiform neurofibroma (PN). For this reason, the activity of vinblastine (VBL) and methotrexate (MTX) was evaluated in children and young adults with NF1 and PN. Patients ≤ 25 years of age with progressive and/or inoperable NF1-PN received VBL 6 mg/m2 and MTX 30 mg/m2 weekly for 26 weeks, followed by every 2 weeks for 26 weeks. Objective response rate was the primary endpoint. Of 25 participants enrolled, 23 were evaluable. The median age of participants was 6.6 years (range 0.3-20.7). The most frequent toxicities were neutropenia and elevation of transaminases. On two-dimensional (2D) imaging, 20 participants (87%) had stable tumor, with a median time to progression of 41.5 months (95% confidence interval 16.9, 64.9). Two of eight participants (25%) with airway involvement demonstrated functional improvements including decreased positive pressure requirements and apnea-hypopnea index. A post hoc three-dimensional (3D) analysis of PN volumes was completed on 15 participants with amenable imaging; 7 participants (46%) had progressive disease on or by the end of therapy. VBL/MTX was well-tolerated but did not result in objective volumetric response. Furthermore, 3D volumetric analysis highlighted the lack of sensitivity of 2D imaging for PN response evaluation.
Collapse
Affiliation(s)
- Chelsea Kotch
- Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Kristina Wagner
- Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
| | - J Harris Broad
- Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
- Department of Anesthesiology, Valley Medical Center, Renton, WA 98055, USA
| | - Eva Dombi
- Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
| | - Jane E Minturn
- Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Peter Phillips
- Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Katherine Smith
- Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
| | - Yimei Li
- Department of Biostatistics, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Ian N Jacobs
- Division of Otolaryngology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
| | - Lisa M Elden
- Division of Otolaryngology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
| | - Michael J Fisher
- Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Jean Belasco
- Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
- Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| |
Collapse
|
6
|
Ooms C, Mossong J, Vergison A, Biver A, Wagner K, Niel O, Parrish A, Abdelrahman TT, de la Fuente Garcia I. Multisystem inflammatory syndrome in children during the first two years of the COVID-19 pandemic in Luxembourg. Front Pediatr 2023; 11:1141074. [PMID: 37090918 PMCID: PMC10113488 DOI: 10.3389/fped.2023.1141074] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/09/2023] [Accepted: 03/06/2023] [Indexed: 04/25/2023] Open
Abstract
Objective Estimate the incidence of multisystem inflammatory syndrome (MIS-C) in children (0-15 years), the role of SARS-CoV-2 variants during the first two years of COVID-19 pandemic in Luxembourg; and describe the demographic, biological and clinical characteristics of the patients. Method Observational retrospective cohort study. Cases between March 2020 and February 2022 were ascertained from the national registry of MIS-C cases by a retrospective review of medical records. Reported SARS-CoV-2 infections were obtained from the national COVID-19 surveillance system. We calculated monthly MIS-C incidence, the ratio between MIS-C and SARS-CoV-2 infections and associated rate ratios by the periods corresponding to the circulation of different variants. Results 18 children were diagnosed with MIS-C among 35,200 reported infections. The incidence rate of MIS-C was 7.2 [95% confidence interval (CI) 4.5-11.4] per 1,000,000 person-months. A higher incidence of MIS-C was observed between September and December 2021, corresponding to the circulation of the Delta variant than during the first year of the pandemic (RR 3.6, 95% CI, 1.1-12.3). The lowest rate of MIS-C per infection was observed during the Omicron (RR 0.17, 95% CI, 0.03-0.82). Median age at diagnosis was 6.5 years. Previously healthy children made up 88% of MIS-C cases, none were vaccinated against SARS-CoV-2. 33% required intensive care. All patients recovered fully. Conclusions MIS-C incidence and MIS-C risk per infection changed significantly over time during the first two years of COVID-19 pandemic. Monitoring of MIS-C incidence in future SARS-CoV-2 waves will be essential to guide public health interventions and vaccination policies for children.
Collapse
Affiliation(s)
- C Ooms
- Clinique Pédiatrique, National Center for Paediatrics, Centre Hospitalier Luxembourg, Luxembourg, Luxembourg
- Department of Paediatrics, Université Catholique de Louvain, Brussels, Belgium
| | - J Mossong
- Health Directorate, Strassen, Luxembourg
| | - A Vergison
- Health Directorate, Strassen, Luxembourg
| | - A Biver
- Clinique Pédiatrique, National Center for Paediatrics, Centre Hospitalier Luxembourg, Luxembourg, Luxembourg
| | - K Wagner
- Clinique Pédiatrique, National Center for Paediatrics, Centre Hospitalier Luxembourg, Luxembourg, Luxembourg
| | - O Niel
- Clinique Pédiatrique, National Center for Paediatrics, Centre Hospitalier Luxembourg, Luxembourg, Luxembourg
| | - A Parrish
- Department of Microbiology, Laboratoire National de Santé, Dudelange, Luxembourg
| | - T T Abdelrahman
- Department of Microbiology, Laboratoire National de Santé, Dudelange, Luxembourg
| | - I de la Fuente Garcia
- Clinique Pédiatrique, National Center for Paediatrics, Centre Hospitalier Luxembourg, Luxembourg, Luxembourg
| |
Collapse
|
7
|
Demel UM, Böger M, Yousefian S, Grunert C, Zhang L, Hotz PW, Gottschlich A, Köse H, Isaakidis K, Vonficht D, Grünschläger F, Rohleder E, Wagner K, Dönig J, Igl V, Brzezicha B, Baumgartner F, Habringer S, Löber J, Chapuy B, Weidinger C, Kobold S, Haas S, Busse AB, Müller S, Wirth M, Schick M, Keller U. Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer. J Clin Invest 2022; 132:152383. [PMID: 35499080 PMCID: PMC9057585 DOI: 10.1172/jci152383] [Citation(s) in RCA: 18] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Accepted: 03/08/2022] [Indexed: 12/11/2022] Open
Abstract
Activated SUMOylation is a hallmark of cancer. Starting from a targeted screening for SUMO-regulated immune evasion mechanisms, we identified an evolutionarily conserved function of activated SUMOylation, which attenuated the immunogenicity of tumor cells. Activated SUMOylation allowed cancer cells to evade CD8+ T cell–mediated immunosurveillance by suppressing the MHC class I (MHC-I) antigen-processing and presentation machinery (APM). Loss of the MHC-I APM is a frequent cause of resistance to cancer immunotherapies, and the pharmacological inhibition of SUMOylation (SUMOi) resulted in reduced activity of the transcriptional repressor scaffold attachment factor B (SAFB) and induction of the MHC-I APM. Consequently, SUMOi enhanced the presentation of antigens and the susceptibility of tumor cells to CD8+ T cell–mediated killing. Importantly, SUMOi also triggered the activation of CD8+ T cells and thereby drove a feed-forward loop amplifying the specific antitumor immune response. In summary, we showed that activated SUMOylation allowed tumor cells to evade antitumor immunosurveillance, and we have expanded the understanding of SUMOi as a rational therapeutic strategy for enhancing the efficacy of cancer immunotherapies.
Collapse
Affiliation(s)
- Uta M. Demel
- Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
- Clinician Scientist Program, Berlin Institute of Health (BIH), Berlin, Germany
| | - Marlitt Böger
- Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | - Schayan Yousefian
- Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- BIH at Charité – Universitätsmedizin Berlin, Berlin, Germany
- Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Corinna Grunert
- Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | - Le Zhang
- Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | - Paul W. Hotz
- Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany
| | - Adrian Gottschlich
- Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany
| | - Hazal Köse
- Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | - Konstandina Isaakidis
- Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | - Dominik Vonficht
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany
- Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany
- Faculty of Biosciences, Heidelberg University, Heidelberg, Germany
| | - Florian Grünschläger
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany
- Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany
- Faculty of Biosciences, Heidelberg University, Heidelberg, Germany
| | - Elena Rohleder
- Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | - Kristina Wagner
- Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany
| | - Judith Dönig
- Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany
| | - Veronika Igl
- Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany
| | | | - Francis Baumgartner
- Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
- Clinician Scientist Program, Berlin Institute of Health (BIH), Berlin, Germany
| | - Stefan Habringer
- Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
- Clinician Scientist Program, Berlin Institute of Health (BIH), Berlin, Germany
| | - Jens Löber
- Department of Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany
| | - Björn Chapuy
- Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- BIH at Charité – Universitätsmedizin Berlin, Berlin, Germany
- Department of Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany
| | - Carl Weidinger
- Gastroenterology, Infectiology and Rheumatology, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Sebastian Kobold
- Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, Munich, Germany
- German Center for Translational Cancer Research (DKTK), DKFZ, Heidelberg, Germany
- DKTK, Partner Site Munich, Munich, Germany
- Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany
| | - Simon Haas
- Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- BIH at Charité – Universitätsmedizin Berlin, Berlin, Germany
- Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany
- Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany
- Faculty of Biosciences, Heidelberg University, Heidelberg, Germany
| | - Antonia B. Busse
- Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | - Stefan Müller
- Institute of Biochemistry II, Goethe University Frankfurt, Medical School, Frankfurt, Germany
| | - Matthias Wirth
- Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
- German Center for Translational Cancer Research (DKTK), DKFZ, Heidelberg, Germany
| | - Markus Schick
- Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | - Ulrich Keller
- Department of Hematology, Oncology and Cancer Immunology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
- German Center for Translational Cancer Research (DKTK), DKFZ, Heidelberg, Germany
| |
Collapse
|
8
|
Wagner K, Reimann S, Budge M, Claydon M, Musicki K, Ban EJ. 479 Penetrating Chest Trauma Causing A Superior Mesenteric Artery-Inferior Vena Cava Fistula and Pancreatic Injury: A Case Report. Br J Surg 2021. [DOI: 10.1093/bjs/znab259.292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Penetrating traumatic injuries can present a challenging scenario due to the potential for multisystem involvement requiring swift collaboration between surgical specialities. We present the case of a 66-year-old female who was stabbed in the right posterior chest. CT revealed a diaphragmatic injury, liver laceration involving segments 6/7 with active bleeding, and a posterior superior mesenteric artery (SMA) to anterior inferior vena cava (IVC) fistula. Due to the proximity of the SMA injury to a replaced right hepatic artery origin, the fistulous connection with the suprarenal IVC, and suspected pancreatic and duodenal injuries, a hybrid rather than a purely endovascular approach was taken. A large compliant occlusion balloon was placed percutaneously in the hepatic IVC. Subsequent trauma laparotomy and right medial visceral rotation identified SMA and SMV injuries, which were repaired with temporary supracoeliac aortic clamping. Further kocherisation of the duodenum revealed a 10 cm longitudinal IVC laceration causing sudden large volume venous haemorrhage. This was repaired after control was gained with supracoeliac aortic clamping, infrarenal IVC vessel loop and balloon inflation. An abdominal VAC dressing was applied. Before transfer to ICU, however, 1L of blood was noted in the VAC cannister and a relook laparotomy demonstrated more than 1L of intrabdominal fresh blood. Bleeding vessels around the uncinate process were ligated. After 48 hours, a relook laparotomy revealed no significant bleeding, and the abdomen was closed. A post-operative MRCP demonstrated pancreatic divisum and likely laceration of the aberrant ventral duct. A subsequent peripancreatic collection was managed conservatively.
Collapse
Affiliation(s)
- K Wagner
- Alfred Health Trauma Unit, Alfred Hospital, Melbourne, Australia
| | - S Reimann
- Department of Vascular Surgery, Alfred Health, Melbourne, Australia
| | - M Budge
- Department of Surgery, Central Clinical School, Monash University, Melbourne, Australia
- Monash University Endocrine Surgery Unit, Alfred Hospital, Melbourne, Australia
| | - M Claydon
- Department of Vascular Surgery, Alfred Health, Melbourne, Australia
| | - K Musicki
- Department of Vascular Surgery, Alfred Health, Melbourne, Australia
| | - E.-Jun Ban
- Alfred Health Trauma Unit, Alfred Hospital, Melbourne, Australia
- Department of Surgery, Central Clinical School, Monash University, Melbourne, Australia
- National Trauma Research Institute and Trauma Service, Alfred Health, Melbourne, Australia
| |
Collapse
|
9
|
Tawil R, Wagner K. CLINICAL RESEARCH. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
10
|
Turner C, Csimma C, De Luca A, Lee J, Wagner K, Wells D, Straub V. REGISTRIES AND CARE OF NMD. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
11
|
Mellion M, Widholm P, Karlsson M, Ahlgren A, Dahlqvist-Leinhard O, Tawil R, Wagner K, Statland J, Wang L, Shieh P, van Engelen B, Cadavid D, Ronco L, Odueyungbo A, Han J, Hatch M. IMAGING. Neuromuscul Disord 2021. [DOI: 10.1016/j.nmd.2021.07.356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Wagner K, Brinkmann J, Bergschmidt A, Renziehausen C, March S. The effects of farming systems (organic vs. conventional) on dairy cow welfare, based on the Welfare Quality® protocol. Animal 2021; 15:100301. [PMID: 34245955 DOI: 10.1016/j.animal.2021.100301] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Revised: 05/25/2021] [Accepted: 05/28/2021] [Indexed: 11/28/2022] Open
Abstract
Animal welfare in livestock production is of great interest to consumers. The organic farming approach strives to ensure animal welfare based on preventive measures, but there are very few scientific studies that compare the actual differences in animal welfare between organic and conventional farms. Those studies that have been carried out frequently focus on specific aspects of animal welfare, mostly health issues. The aim of the present study, therefore, was to investigate the effects of the farming system on the welfare of dairy cows in a more holistic way. Although this study was carried out in just two federal states of Germany, the results could serve as a suitable model for the whole country. We used the Welfare Quality assessment protocol to measure welfare for dairy cattle (Welfare Quality®, 2009) and the results showed significant differences (P < 0.05) between organic and conventional farms, but there was also considerable variance between individual farms of the same farming system. Organic farms scored higher in all four Welfare Quality® principles: "Good Feeding", "Good Housing", "Good Health" and "Appropriate Behavior" compared to conventional farms. In particular, organic farms obtained higher scores with respect to Welfare Quality® measures of resting comfort, which contributes to a lower percentage of lameness; organic farms also implemented less painful methods for disbudding, or indeed carried out no disbudding, and provided access to pasture and outdoor exercise. However, organic farms still have room for improvement, especially with respect to animal health. Therefore, outcome-based specifications should be included in the current (purely action-oriented) European regulation of organic production (EC, 2008; EU, 2018) to safeguard the health-related aspects of animal welfare.
Collapse
Affiliation(s)
- K Wagner
- Thünen Institute of Organic Farming, Trenthorst 32, 23847 Westerau, Germany
| | - J Brinkmann
- Thünen Institute of Organic Farming, Trenthorst 32, 23847 Westerau, Germany.
| | - A Bergschmidt
- Thünen Institute of Farm Economics, Bundesallee 50, 38116 Braunschweig, Germany
| | - C Renziehausen
- Thünen Institute of Farm Economics, Bundesallee 50, 38116 Braunschweig, Germany
| | - S March
- Thünen Institute of Organic Farming, Trenthorst 32, 23847 Westerau, Germany
| |
Collapse
|
13
|
Wagner K, Boehle A, Pathak P, Kasper M, Arsenault R, Jakob G, Käufl U, Leveratto S, Maire AL, Pantin E, Siebenmorgen R, Zins G, Absil O, Ageorges N, Apai D, Carlotti A, Choquet É, Delacroix C, Dohlen K, Duhoux P, Forsberg P, Fuenteseca E, Gutruf S, Guyon O, Huby E, Kampf D, Karlsson M, Kervella P, Kirchbauer JP, Klupar P, Kolb J, Mawet D, N'Diaye M, de Xivry GO, Quanz SP, Reutlinger A, Ruane G, Riquelme M, Soenke C, Sterzik M, Vigan A, de Zeeuw T. Author Correction: Imaging low-mass planets within the habitable zone of α Centauri. Nat Commun 2021; 12:2651. [PMID: 33953194 PMCID: PMC8099858 DOI: 10.1038/s41467-021-23145-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
- K Wagner
- Dept. of Astronomy and Steward Observatory, University of Arizona, Tucson, AZ, USA. .,NASA Nexus for Exoplanet System Science, Earths in Other Solar Systems Team, Tucson, AZ, USA.
| | - A Boehle
- Institute for Particle Physics and Astrophysics, ETH Zurich, Zürich, Switzerland
| | - P Pathak
- European Southern Observatory, Garching bei München, Germany
| | - M Kasper
- European Southern Observatory, Garching bei München, Germany
| | - R Arsenault
- European Southern Observatory, Garching bei München, Germany
| | - G Jakob
- European Southern Observatory, Garching bei München, Germany
| | - U Käufl
- European Southern Observatory, Garching bei München, Germany
| | - S Leveratto
- European Southern Observatory, Garching bei München, Germany
| | - A-L Maire
- STAR Institute, Université de Liège, Liège, Belgium
| | - E Pantin
- AIM, CEA, CNRS, Université Paris-Saclay, Université Paris Diderot, Sorbonne Paris Cité, Gif-sur-Yvette, France
| | - R Siebenmorgen
- European Southern Observatory, Garching bei München, Germany
| | - G Zins
- European Southern Observatory, Garching bei München, Germany
| | - O Absil
- STAR Institute, Université de Liège, Liège, Belgium
| | - N Ageorges
- Kampf Telescope Optics, München, Germany
| | - D Apai
- Dept. of Astronomy and Steward Observatory, University of Arizona, Tucson, AZ, USA.,NASA Nexus for Exoplanet System Science, Earths in Other Solar Systems Team, Tucson, AZ, USA.,Lunar and Planetary Laboratory, University of Arizona, Tucson, AZ, USA
| | - A Carlotti
- Univ. Grenoble Alpes, CNRS, IPAG, Grenoble, France
| | - É Choquet
- Aix Marseille Univ, CNRS, CNES, LAM, Marseille, France
| | - C Delacroix
- STAR Institute, Université de Liège, Liège, Belgium
| | - K Dohlen
- Aix Marseille Univ, CNRS, CNES, LAM, Marseille, France
| | - P Duhoux
- European Southern Observatory, Garching bei München, Germany
| | - P Forsberg
- Department of Materials Science and Engineering, Ångström Laboratory, Uppsala University, Uppsala, Sweden
| | - E Fuenteseca
- European Southern Observatory, Garching bei München, Germany
| | - S Gutruf
- Kampf Telescope Optics, München, Germany
| | - O Guyon
- Dept. of Astronomy and Steward Observatory, University of Arizona, Tucson, AZ, USA.,Subaru Telescope, National Astronomical Observatory of Japan, National Institutes of Natural Sciences (NINS), Hilo, HI, USA.,The Breakthrough Initiatives, NASA Research Park, Moffett Field, CA, USA.,James C. Wyant College of Optical Sciences, University of Arizona, Tucson, AZ, USA
| | - E Huby
- LESIA, Observatoire de Paris, Meudon, France
| | - D Kampf
- Kampf Telescope Optics, München, Germany
| | - M Karlsson
- Department of Materials Science and Engineering, Ångström Laboratory, Uppsala University, Uppsala, Sweden
| | - P Kervella
- LESIA, Observatoire de Paris, Meudon, France
| | - J-P Kirchbauer
- European Southern Observatory, Garching bei München, Germany
| | - P Klupar
- The Breakthrough Initiatives, NASA Research Park, Moffett Field, CA, USA
| | - J Kolb
- European Southern Observatory, Garching bei München, Germany
| | - D Mawet
- California Institute of Technology, Pasadena, CA, USA
| | - M N'Diaye
- Université Côte d'Azur, Observatoire de la Côte d'Azur, CNRS, Laboratoire Lagrange, Nice, France
| | | | - S P Quanz
- Institute for Particle Physics and Astrophysics, ETH Zurich, Zürich, Switzerland
| | | | - G Ruane
- California Institute of Technology, Pasadena, CA, USA.,Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA, USA
| | - M Riquelme
- European Southern Observatory, Garching bei München, Germany
| | - C Soenke
- European Southern Observatory, Garching bei München, Germany
| | - M Sterzik
- European Southern Observatory, Garching bei München, Germany
| | - A Vigan
- Aix Marseille Univ, CNRS, CNES, LAM, Marseille, France
| | - T de Zeeuw
- European Southern Observatory, Garching bei München, Germany.,Sterrewacht Leiden, Leiden University, Leiden, The Netherlands.,Max Planck Institute for Extraterrestrial Physics, Garching, Germany
| |
Collapse
|
14
|
Schultheiss K, Sato N, Matthies P, Körber L, Wagner K, Hula T, Gladii O, Pearson JE, Hoffmann A, Helm M, Fassbender J, Schultheiss H. Time Refraction of Spin Waves. Phys Rev Lett 2021; 126:137201. [PMID: 33861132 DOI: 10.1103/physrevlett.126.137201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/09/2020] [Accepted: 03/04/2021] [Indexed: 06/12/2023]
Abstract
We present an experimental study of time refraction of spin waves (SWs) propagating in microscopic waveguides under the influence of time-varying magnetic fields. Using space- and time-resolved Brillouin light scattering microscopy, we demonstrate that the broken translational symmetry along the time coordinate results in a loss of energy conservation for SWs and thus allows for a broadband and controllable shift of the SW frequency. With an integrated design of SW waveguide and microscopic current line for the generation of strong, nanosecond-long, magnetic field pulses, a conversion efficiency up to 39% of the carrier SW frequency is achieved, significantly larger compared to photonic systems. Given the strength of the magnetic field pulses and its strong impact on the SW dispersion relation, the effect of time refraction can be quantified on a length scale comparable to the SW wavelength. Furthermore, we utilize time refraction to excite SW bursts with pulse durations in the nanosecond range and a frequency shift depending on the pulse polarity.
Collapse
Affiliation(s)
- K Schultheiss
- Helmholtz-Zentrum Dresden - Rossendorf, Institute of Ion Beam Physics and Materials Research, 01328 Dresden, Germany
| | - N Sato
- Helmholtz-Zentrum Dresden - Rossendorf, Institute of Ion Beam Physics and Materials Research, 01328 Dresden, Germany
| | - P Matthies
- Helmholtz-Zentrum Dresden - Rossendorf, Institute of Ion Beam Physics and Materials Research, 01328 Dresden, Germany
- Fakultät Physik, Technische Universität Dresden, 01062 Dresden, Germany
| | - L Körber
- Helmholtz-Zentrum Dresden - Rossendorf, Institute of Ion Beam Physics and Materials Research, 01328 Dresden, Germany
- Fakultät Physik, Technische Universität Dresden, 01062 Dresden, Germany
| | - K Wagner
- Helmholtz-Zentrum Dresden - Rossendorf, Institute of Ion Beam Physics and Materials Research, 01328 Dresden, Germany
| | - T Hula
- Helmholtz-Zentrum Dresden - Rossendorf, Institute of Ion Beam Physics and Materials Research, 01328 Dresden, Germany
| | - O Gladii
- Helmholtz-Zentrum Dresden - Rossendorf, Institute of Ion Beam Physics and Materials Research, 01328 Dresden, Germany
| | - J E Pearson
- Materials Science Division, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - A Hoffmann
- Materials Science Division, Argonne National Laboratory, Argonne, Illinois 60439, USA
| | - M Helm
- Helmholtz-Zentrum Dresden - Rossendorf, Institute of Ion Beam Physics and Materials Research, 01328 Dresden, Germany
- Fakultät Physik, Technische Universität Dresden, 01062 Dresden, Germany
| | - J Fassbender
- Helmholtz-Zentrum Dresden - Rossendorf, Institute of Ion Beam Physics and Materials Research, 01328 Dresden, Germany
- Fakultät Physik, Technische Universität Dresden, 01062 Dresden, Germany
| | - H Schultheiss
- Helmholtz-Zentrum Dresden - Rossendorf, Institute of Ion Beam Physics and Materials Research, 01328 Dresden, Germany
- Fakultät Physik, Technische Universität Dresden, 01062 Dresden, Germany
| |
Collapse
|
15
|
Porto A, Rubin K, Wagner K, Chang W, Macri G, Anderson D. Impact of Pediatric Electronic Consultations in a Federally Qualified Health Center. Telemed J E Health 2021; 27:1379-1384. [PMID: 33719584 DOI: 10.1089/tmj.2020.0394] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background: Access to pediatric specialty care is a challenge, particularly for medically underserved populations. Introduction: One evolving method that has shown promise in helping ameliorate this disparity is electronic consultations (e-consults). Materials and Methods: This retrospective cohort study compared two groups: patients referred to pediatric cardiology, endocrinology, or pulmonology from a Federally-Qualified Health Center 10 months before the implementation of an evidence-based care pathway and those referred in the 10 months after implementation. The care pathway included evidence-based referral guidelines for common pediatric diagnoses and an e-consult process. Data included patient demographics, dates of referral requests, appointment dates, e-consult response dates and times, diagnosis codes, and consultants' recommendations. Results: Twenty-three percent of all referrals made postimplementation were submitted for an e-consult, with 53% preventing an unnecessary face-to-face visit. The most common reason for an e-consult was heart murmur/chest pain for cardiology, short stature for endocrinology, and asthma for pulmonology. Discussion: Providers used e-consults for nearly one-quarter of all consultations postimplementation, resulting in 17% of consultations not needing a face-to-face visit. The use of e-consults combined with evidence-based referral guidelines provided a useful tool to help front line pediatric primary care providers manage complex problems and identify those not needing to see a specialist in person. Conclusions: Evidence-based care pathways combined with e-consults can help improve access to pediatric specialty care by reducing demand for in-person visits and allowing more care to be delivered in primary care.
Collapse
Affiliation(s)
| | - Karen Rubin
- UConn School of Medicine, Farmington, Connecticut, USA.,Connecticut Children's Medical Center, Center for Innovation, Hartford, Connecticut, USA
| | | | - Wei Chang
- Weitzman Institute, Middletown, Connecticut, USA
| | | | | |
Collapse
|
16
|
Mohamud Yusuf A, Hagemann N, Schulten S, Rausch O, Wagner K, Hussner T, Qi Y, Totzeck M, Kleinschnitz C, Squire A, Gunzer M, Hermann DM. Light Sheet Microscopy Using FITC-Albumin Followed by Immunohistochemistry of the Same Rehydrated Brains Reveals Ischemic Brain Injury and Early Microvascular Remodeling. Front Cell Neurosci 2021; 14:625513. [PMID: 33469420 PMCID: PMC7813928 DOI: 10.3389/fncel.2020.625513] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2020] [Accepted: 12/07/2020] [Indexed: 11/13/2022] Open
Abstract
Until recently, the visualization of cerebral microvessels was hampered by the fact that only short segments of vessels could be evaluated in brain sections by histochemistry. These limitations have been overcome by light sheet microscopy, which allows the 3D analysis of microvasculature in cleared brains. A major limitation of light sheet microscopy is that antibodies do not sufficiently penetrate cleared brains. We herein describe a technique of reverse clearing and rehydration, which after microvascular network analysis allows brain sectioning and immunohistochemistry employing a broad set of antibodies. Performing light sheet microscopy on brains of mice exposed to intraluminal middle cerebral artery occlusion (MCAO), we show that in the early phase of microvascular remodeling branching point density was markedly reduced, more strongly than microvascular length. Brain infarcts in light sheet microscopy were sharply demarcated by their autofluorescence signal, closely corresponding to brain infarcts revealed by Nissl staining. Neuronal survival, leukocyte infiltration, and astrocytic reactivity could be evaluated by immunohistochemistry in rehydrated brains, as shown in direct comparisons with non-cleared brains. Immunohistochemistry revealed microthrombi in ischemic microvessels that were likely responsible for the marked branching point loss. The balance between microvascular thrombosis and remodeling warrants further studies at later time-points after stroke.
Collapse
Affiliation(s)
- Ayan Mohamud Yusuf
- Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Nina Hagemann
- Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Sarah Schulten
- Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Olessja Rausch
- Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Kristina Wagner
- Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Tanja Hussner
- Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Yachao Qi
- Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Matthias Totzeck
- Department of Cardiology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Christoph Kleinschnitz
- Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Anthony Squire
- Institute for Experimental Immunology and Imaging, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - Matthias Gunzer
- Institute for Experimental Immunology and Imaging, University Hospital Essen, University Duisburg-Essen, Essen, Germany.,Leibniz Institute for Analytical Sciences ISAS e.V., Dortmund, Germany
| | - Dirk M Hermann
- Department of Neurology, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| |
Collapse
|
17
|
Weber T, Wagner K. Replacing fetal bovine serum (FBS) in research and testing. ALTEX 2021; 38:163-164. [PMID: 33452533 DOI: 10.14573/altex.2012141] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/15/2020] [Accepted: 12/15/2020] [Indexed: 11/23/2022]
Affiliation(s)
- Tilo Weber
- Animal Welfare Academy of the German Animal Welfare Federation, Neubiberg, Germany
| | - Kristina Wagner
- Animal Welfare Academy of the German Animal Welfare Federation, Neubiberg, Germany
| |
Collapse
|
18
|
de Jong G, Bartels L, Kedde M, Verdegaal EME, Gillissen MA, Levie SE, Cercel MG, van Hal-van Veen SE, Fatmawati C, van de Berg D, Yasuda E, Claassen YB, Bakker AQ, van der Burg SH, Schotte R, Villaudy J, Spits H, Hazenberg MD, van Helden PM, Wagner K. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo. Cancer Immunol Immunother 2020; 70:1569-1581. [PMID: 33225419 DOI: 10.1007/s00262-020-02780-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Accepted: 10/22/2020] [Indexed: 01/13/2023]
Abstract
Targeted cancer therapy with monoclonal antibodies has proven successful for different cancer types but is limited by the availability of suitable antibody targets. CD43s, a unique sialylated form of CD43 expressed by hematologic malignancies, is a recently identified target and antibodies interacting with CD43s may have therapeutic potential against acute myeloid leukemia (AML) and myelodysplastic syndrome. CD43s is recognized by the human antibody AT1413, that was derived from a high-risk AML patient who successfully cleared leukemia after allogeneic stem cell transplantation. Here we observed that AT1413 binds also to certain non-hematopoietic tumor cells, particularly melanoma and breast cancer. AT1413 immune precipitated CD43s from melanoma cells confirming that it recognizes the same target on melanoma as on AML. AT1413 induced antibody-dependent cellular cytotoxicity against short-term cultured patient-derived melanoma samples. However, AT1413 was unable to affect the growth of melanoma cells in vivo. To increase the efficacy of AT1413 as a therapeutic antibody, we generated two different formats of bispecific T-cell engaging antibodies (TCEs): one binding bivalently (bTCE) and the other monovalently (knob-in-hole; KiH) to both CD43s and CD3ε. In vitro, these TCEs redirected T-cell cytotoxicity against melanoma cells with differences in potencies. To investigate their effects in vivo, we grafted mice that harbor a human immune system with the melanoma cell line A375. Treatment with both AT1413 bTCE and AT1413 KiH significantly reduced tumor outgrowth in these mice. These data indicate a broad therapeutic potential of AT1413 that includes AML and CD43s-expressing solid tumors that originate from CD43-negative tissues.
Collapse
Affiliation(s)
- G de Jong
- AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands.,Department of Hematology, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands.,Cancer Center Amsterdam (CCA), Amsterdam, The Netherlands.,Amsterdam Infection and Immunity Institute (AI&II), Amsterdam, The Netherlands
| | - L Bartels
- AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands.,Amsterdam Infection and Immunity Institute (AI&II), Amsterdam, The Netherlands
| | - M Kedde
- AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands
| | - E M E Verdegaal
- Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands
| | - M A Gillissen
- AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands.,Department of Hematology, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands.,Cancer Center Amsterdam (CCA), Amsterdam, The Netherlands.,Amsterdam Infection and Immunity Institute (AI&II), Amsterdam, The Netherlands
| | - S E Levie
- AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands
| | - M G Cercel
- AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands
| | | | - C Fatmawati
- AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands
| | - D van de Berg
- AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands
| | - E Yasuda
- AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands
| | - Y B Claassen
- AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands
| | - A Q Bakker
- AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands
| | - S H van der Burg
- Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands
| | - R Schotte
- AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands
| | - J Villaudy
- AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands
| | - H Spits
- AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands.,Amsterdam Infection and Immunity Institute (AI&II), Amsterdam, The Netherlands.,Department of Experimental Immunology, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands
| | - M D Hazenberg
- Department of Hematology, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands.,Cancer Center Amsterdam (CCA), Amsterdam, The Netherlands.,Amsterdam Infection and Immunity Institute (AI&II), Amsterdam, The Netherlands.,Department of Hematopoiesis, Sanquin Research, Amsterdam, The Netherlands
| | - P M van Helden
- AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands.
| | - K Wagner
- AIMM Therapeutics, Meibergdreef 59, 1105 BA, Amsterdam, The Netherlands
| |
Collapse
|
19
|
Wagner K, Franklin K, Larona A, Zhang L, Tian X. P502 BUDESONIDE 128UG AND 256UG SIGNIFICANTLY RELIEVES MODERATE-TO-SEVERE PAR NASAL SYMPTOMS AND CONGESTION. Ann Allergy Asthma Immunol 2020. [DOI: 10.1016/j.anai.2020.08.160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
20
|
Johnson N, Statland J, Weihl C, Bates K, Amato A, Kang P, Lowes L, Mathews K, Mozaffar T, Straub V, Wagner K, Heatwole C. LIMB GIRDLE MUSCULAR DYSTROPHIES. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
21
|
Mellion M, Tawil R, Ronco L, Rahilly A, Rojas A, Odueyungbo A, Wagner K, Statland J, Wang L, Genge A, Gibson S, Goyal N, Hamel J, Johnson N, Lochmuller H, LoRusso S, Pestronk A, Sacconi S, Shieh P, Cadavid D, Group RS. FSHD / OPMD / MYOTONIC DYSTROPHY. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
22
|
Hayward L, Guo D, Wagner K, King O, Emerson C. FSHD / OPMD / MYOTONIC DYSTROPHY. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
23
|
Miller D, Vaidya S, Jauernig J, Ethell B, Wagner K, Radhakrishnan R, Tillmann HC. Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients. Respir Res 2020; 21:248. [PMID: 32967685 PMCID: PMC7513528 DOI: 10.1186/s12931-020-01501-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Accepted: 09/06/2020] [Indexed: 12/02/2022] Open
Abstract
Background Indacaterol maleate delivered with the Breezhaler® inhalation device is a long-acting β2-agonist approved for chronic obstructive pulmonary disease. In the development of a once daily, inhaled fixed dose combination (FDC) of indacaterol, glycopyrronium bromide (a long-acting muscarinic antagonist), and mometasone furoate (an inhaled corticosteroid [ICS]) for the treatment of patients with asthma, the acetate salt of indacaterol is used instead of the maleate salt. Here, we investigated the lung function, pharmacokinetics (PK) and safety of indacaterol maleate 150 μg once daily (o.d.) and indacaterol acetate 150 μg o.d. in comparison with placebo. Methods This was a randomised, double-blind, three-period crossover study (ClinicalTrials.gov identifier, NCT03257995) in patients with asthma on background ICS therapy. Patients with percent predicted pre-bronchodilator forced expiratory volume per second (FEV1) ≥50% and ≤ 90% were included in the study. Patients received indacaterol maleate 150 μg o.d., indacaterol acetate 150 μg o.d., or placebo on top of stable background ICS in randomised sequence. Trough FEV1 was assessed after 14 days of treatment. PK of indacaterol salts were assessed at steady state after 14 days of treatment; peak expiratory flow (PEF) rate and rescue medication use were collected with a combined PEF-meter/electronic diary throughout the study. Results Of the 54 adult patients (median age of 48 years), 51 patients completed the study. Both indacaterol salts demonstrated statistically significant improvements in trough FEV1 of 186 mL (maleate) and 146 mL (acetate) compared with placebo (both P < 0.001). FEV1 AUC0-4h improved by 248 mL (maleate) and 245 mL (acetate), and PEF by 33 L/min (maleate) and 30.8 L/min (acetate) versus placebo. Systemic exposure of indacaterol (AUC0-24h,ss and Cmax,ss on Day 14) was comparable after administration of both salt forms. Both salt forms demonstrated a good safety profile and were well tolerated, with a difference in the reporting frequency of AEs of coughing (maleate, 23.5%; acetate, 0%). Conclusions In patients with asthma, indacaterol maleate and acetate elicited comparable and significant improvements in lung function compared with placebo and achieved comparable systemic exposure. Both indacaterol salts were safe and well tolerated. Trial registration ClinicalTrials.gov NCT03257995 June 06, 2017
Collapse
Affiliation(s)
- David Miller
- Northeast Medical Research Associates Inc., North Dartmouth, MA, USA
| | | | | | - Brian Ethell
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | - Kristina Wagner
- Novartis Institutes for Biomedical Research, Cambridge, MA, USA
| | | | | |
Collapse
|
24
|
Jordan SC, Kucher K, Bagger M, Hockey HU, Wagner K, Ammerman N, Vo A. Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab. Am J Transplant 2020; 20:2581-2588. [PMID: 32301258 DOI: 10.1111/ajt.15922] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2019] [Revised: 03/20/2020] [Accepted: 04/02/2020] [Indexed: 01/25/2023]
Abstract
Awareness of drug-drug interactions is critical in organ transplant recipient management. However, biologic agents interfering with monoclonal antibodies is not widely considered. We report the effect of high-dose intravenous immunoglobulin (IVIg) on safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the human anti-C5 monoclonal antibody tesidolumab (LFG316) in end-stage renal disease patients awaiting kidney transplant. In this single-center, phase 1, open-label, parallel-group study, 8 patients were assigned to receive either single-dose tesidolumab + IVIg or tesidolumab alone, with 56-day follow-up. Within-group PK parameters were consistent. Mean tesidolumab exposure decreased 34%, clearance increased 63%, and half-life decreased 41% comparing tesidolumab + IVIg to tesidolumab alone. IVIg influence on tesidolumab elimination was most evident in the first 3 weeks. Complete suppression of both total and alternative complement activities was maintained for 4 weeks in the tesidolumab alone group and for 2 weeks in the tesidolumab + IVIg group. Tesidolumab was well tolerated. IVIg infused before tesidolumab affected tesidolumab PK and PD, resulting in a shortened period of full complement activity inhibition. These findings suggest a clinically relevant impact of IVIg on monoclonal antibody clearance and indirectly hint at an IVIg mechanism of action in treating autoimmune diseases and allosensitization by accelerating pathogenic IgG antibody degradation. Trial registration number: NCT02878616.
Collapse
Affiliation(s)
- Stanley C Jordan
- Comprehensive Transplant Center, Transplant Immunotherapy Program Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Klaus Kucher
- Novartis Institutes for BioMedical Research, Basel, Switzerland
| | - Morten Bagger
- Novartis Institutes for BioMedical Research, Basel, Switzerland
| | | | - Kristina Wagner
- Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA
| | - Noriko Ammerman
- Comprehensive Transplant Center, Transplant Immunotherapy Program Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Ashley Vo
- Comprehensive Transplant Center, Transplant Immunotherapy Program Cedars-Sinai Medical Center, Los Angeles, California, USA
| |
Collapse
|
25
|
Schotte R, Villaudy J, Kedde M, Pos W, Wagner K, Go D, Fatmawati C, Moiset G, Yasuda E, Cercel M, Frankin E, van Hal-van Veen S, van Helden P, Verdegaal E, van Eenennaam H, van der Burg S, Spits H. 580P AT1412, a patient-derived CD9 antibody promotes tumour immune infiltration and induces tumour rejection. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.694] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
26
|
Keiten-Schmitz J, Wagner K, Piller T, Kaulich M, Alberti S, Müller S. The Nuclear SUMO-Targeted Ubiquitin Quality Control Network Regulates the Dynamics of Cytoplasmic Stress Granules. Mol Cell 2020; 79:54-67.e7. [PMID: 32521226 DOI: 10.1016/j.molcel.2020.05.017] [Citation(s) in RCA: 63] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Revised: 03/06/2020] [Accepted: 05/12/2020] [Indexed: 01/01/2023]
Abstract
Exposure of cells to heat or oxidative stress causes misfolding of proteins. To avoid toxic protein aggregation, cells have evolved nuclear and cytosolic protein quality control (PQC) systems. In response to proteotoxic stress, cells also limit protein synthesis by triggering transient storage of mRNAs and RNA-binding proteins (RBPs) in cytosolic stress granules (SGs). We demonstrate that the SUMO-targeted ubiquitin ligase (StUbL) pathway, which is part of the nuclear proteostasis network, regulates SG dynamics. We provide evidence that inactivation of SUMO deconjugases under proteotoxic stress initiates SUMO-primed, RNF4-dependent ubiquitylation of RBPs that typically condense into SGs. Impairment of SUMO-primed ubiquitylation drastically delays SG resolution upon stress release. Importantly, the StUbL system regulates compartmentalization of an amyotrophic lateral sclerosis (ALS)-associated FUS mutant in SGs. We propose that the StUbL system functions as surveillance pathway for aggregation-prone RBPs in the nucleus, thereby linking the nuclear and cytosolic axis of proteotoxic stress response.
Collapse
Affiliation(s)
- Jan Keiten-Schmitz
- Institute of Biochemistry II, Goethe University, Faculty of Medicine, Frankfurt, Germany
| | - Kristina Wagner
- Institute of Biochemistry II, Goethe University, Faculty of Medicine, Frankfurt, Germany
| | - Tanja Piller
- Institute of Biochemistry II, Goethe University, Faculty of Medicine, Frankfurt, Germany
| | - Manuel Kaulich
- Institute of Biochemistry II, Goethe University, Faculty of Medicine, Frankfurt, Germany
| | - Simon Alberti
- CMCB/BIOTEC, Technical University Dresden, Dresden, Germany
| | - Stefan Müller
- Institute of Biochemistry II, Goethe University, Faculty of Medicine, Frankfurt, Germany.
| |
Collapse
|
27
|
Metternich B, Spanhel K, Schoendube A, Ofer I, Geiger MJ, Schulze-Bonhage A, Mast H, Wagner K. Flashbulb memory recall in healthy adults - a functional magnetic resonance imaging study. Memory 2020; 28:461-472. [PMID: 32290772 DOI: 10.1080/09658211.2020.1733022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
The present study investigated neural activations related to flashbulb memory (FM) recall and examined whether the amygdala and hippocampus are involved in FM recall. 20 healthy adults completed a block design with an FM-condition, where the reception events for a number of potential FM events had to be recalled, and a control condition (FMC) comprising reception events lacking FM characteristics. A definition naming task was used as an implicit baseline. The individual emotional reaction to the FM events (EMO) and self-rated retrieval success were included in the SPM model as modulating parameters. The main contrast of interest were FM > FMC and activations associated with EMO. ROI-analyses on mesiotemporal regions were performed. FM > FMC yielded activations in line with the autobiographical memory network, with mostly left sided-activations. EMO was associated with a more bilateral activation pattern. ROI-analysis revealed activations for EMO in the right amygdala and HATA. FM > FMC was associated with right hippocampal activations. The present findings are compatible with previous research into autobiographical memory, but also show activations for FM recall different from ordinary, not highly emotional autobiographical memories, as EMO is associated with a more bilateral network. Moreover, the amygdala seems to be involved in FM recall.
Collapse
Affiliation(s)
- B Metternich
- Epilepsy Center, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany
| | - K Spanhel
- Department of Psychology, University of Freiburg, Freiburg im Breisgau, Germany
| | - A Schoendube
- Department of Psychology, University of Freiburg, Freiburg im Breisgau, Germany
| | - I Ofer
- Epilepsy Center, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany
| | - M J Geiger
- Epilepsy Center, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany
| | - A Schulze-Bonhage
- Epilepsy Center, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany
| | - H Mast
- Clinic for Radiology, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany
| | - K Wagner
- Epilepsy Center, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany
| |
Collapse
|
28
|
Abstract
On the basis of interviews with management and factory floor employees at 45 matched firms in Britain and West Germany, this article examines the roles of machinery and workforce skills in explaining comparative produc tivity performance. The average age of British machinery was not very different from that found in German plants, but it was less technically advanced, was subject to more frequent breakdowns and breakdowns took longer to correct. Productivity was higher in Germany in each of our matched product groups and the importance of skills at all levels was apparent.
Collapse
|
29
|
Zotz G, Kappert N, Müller LLB, Wagner K. Temperature dependence of germination and growth in Anthurium (Araceae). Plant Biol (Stuttg) 2020; 22:184-190. [PMID: 31652363 DOI: 10.1111/plb.13063] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/20/2019] [Accepted: 10/16/2019] [Indexed: 06/10/2023]
Abstract
By the year 2100, temperatures are predicted to increase by about 6 °C at higher latitudes and about 3 °C in the tropics. In spite of the smaller increase in the tropics, consequences may be more severe because the climatic niches of tropical species are generally assumed to be rather narrow due to a high degree of climate stability and higher niche specialisation. However, rigorous data to back up this notion are rare. We chose the megadiverse genus Anthurium (Araceae) for study. Considering that the regeneration niche of a species is crucial for overall niche breadth, we focused on the response of germination and early growth through a temperature range of 24 °C of 15 Anthurium species, and compared the thermal niche breadth (TNB) with the temperature conditions in their current range, modelled from occurrence records. Surprisingly, an increase of 3 °C would lead to a larger overlap of TNB of germination and modelled in situ temperature conditions, while the overlap of TNB of growth with in situ conditions under current and future conditions is statistically indistinguishable. We conclude that future temperatures tend to be closer to the thermal optima of most species. Whether this really leads to an increase in performance depends on other abiotic and biotic factors, most prominently potentially changing precipitation patterns.
Collapse
Affiliation(s)
- G Zotz
- Carl von Ossietzky Universität Oldenburg, Institut für Biologie und Umweltwissenschaften, AG Funktionelle Ökologie der Pflanzen, Oldenburg, Germany
- Smithsonian Tropical Research Institute, Balboa, Ancon, Panamá, República de Panamá
| | - N Kappert
- Carl von Ossietzky Universität Oldenburg, Institut für Biologie und Umweltwissenschaften, AG Funktionelle Ökologie der Pflanzen, Oldenburg, Germany
| | - L-L B Müller
- Carl von Ossietzky Universität Oldenburg, Institut für Biologie und Umweltwissenschaften, AG Funktionelle Ökologie der Pflanzen, Oldenburg, Germany
| | - K Wagner
- Carl von Ossietzky Universität Oldenburg, Institut für Biologie und Umweltwissenschaften, AG Funktionelle Ökologie der Pflanzen, Oldenburg, Germany
| |
Collapse
|
30
|
Katona L, Hartwich K, Tomioka R, Somogyi J, Roberts JDB, Wagner K, Joshi A, Klausberger T, Rockland KS, Somogyi P. Synaptic organisation and behaviour-dependent activity of mGluR8a-innervated GABAergic trilaminar cells projecting from the hippocampus to the subiculum. Brain Struct Funct 2020; 225:705-734. [PMID: 32016558 PMCID: PMC7046583 DOI: 10.1007/s00429-020-02029-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2019] [Accepted: 01/16/2020] [Indexed: 02/07/2023]
Abstract
In the hippocampal CA1 area, the GABAergic trilaminar cells have their axon distributed locally in three layers and also innervate the subiculum. Trilaminar cells have a high level of somato-dendritic muscarinic M2 acetylcholine receptor, lack somatostatin expression and their presynaptic inputs are enriched in mGluR8a. But the origin of their inputs and their behaviour-dependent activity remain to be characterised. Here we demonstrate that (1) GABAergic neurons with the molecular features of trilaminar cells are present in CA1 and CA3 in both rats and mice. (2) Trilaminar cells receive mGluR8a-enriched GABAergic inputs, e.g. from the medial septum, which are probably susceptible to hetero-synaptic modulation of neurotransmitter release by group III mGluRs. (3) An electron microscopic analysis identifies trilaminar cell output synapses with specialised postsynaptic densities and a strong bias towards interneurons as targets, including parvalbumin-expressing cells in the CA1 area. (4) Recordings in freely moving rats revealed the network state-dependent segregation of trilaminar cell activity, with reduced firing during movement, but substantial increase in activity with prolonged burst firing (> 200 Hz) during slow wave sleep. We predict that the behaviour-dependent temporal dynamics of trilaminar cell firing are regulated by their specialised inhibitory inputs. Trilaminar cells might support glutamatergic principal cells by disinhibition and mediate the binding of neuronal assemblies between the hippocampus and the subiculum via the transient inhibition of local interneurons.
Collapse
Affiliation(s)
- Linda Katona
- Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK.
| | - Katja Hartwich
- Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK
| | - Ryohei Tomioka
- Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK
- Laboratory for Cortical Organization and Systematics, RIKEN Brain Science Institute, Wako, Saitama, 351-0198, Japan
- Department of Morphological Neural Science, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
| | - Jozsef Somogyi
- Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK
| | - J David B Roberts
- Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK
| | - Kristina Wagner
- Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK
| | - Abhilasha Joshi
- Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK
- Department of Physiology, Kavli Institute for Fundamental Neuroscience, University of California, San Francisco, CA, USA
| | - Thomas Klausberger
- Center for Brain Research, Division of Cognitive Neurobiology, Medical University of Vienna, 1090, Vienna, Austria
| | - Kathleen S Rockland
- Laboratory for Cortical Organization and Systematics, RIKEN Brain Science Institute, Wako, Saitama, 351-0198, Japan
- Department of Anatomy and Neurobiology, Boston University School of Medicine, 72 East Concord St., Boston, MA, 02118, USA
| | - Peter Somogyi
- Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK.
| |
Collapse
|
31
|
Wolf-Brandstetter C, Beutner R, Hess R, Bierbaum S, Wagner K, Scharnweber D, Gbureck U, Moseke C. Multifunctional calcium phosphate based coatings on titanium implants with integrated trace elements. Biomed Mater 2020; 15:025006. [DOI: 10.1088/1748-605x/ab5d7b] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
32
|
Thalmann A, Wagner K, Tomassen M, Driessen J, de Jong J, Antalick J, Biancotto G, Cowles J, Felgueiras I, Haustraete K, Johannsen F, Muhonen; R, Nunes da Costa J, Pløger A, Shearan P, van der Kamp H, van Schalm K, Wagner K. Liquid Chromatographic Method to Determine Narasin in Feedingstuffs and Premixtures: Development, Validation, and Interlaboratory Study. J AOAC Int 2019. [DOI: 10.1093/jaoac/87.6.1278] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
A reversed-phase liquid chromatography (LC) method for narasin in feedingstuffs and premixtures was developed, validated, and interlaboratory studied. The extraction solvent was methanol–K2HPO4 solution (9 + 1, v/v). Narasin was detected at 600 nm after post-column derivatization with dimethylamino-benzaldehyde. Recovery was >90%. The repeatability (RSDr) in feed (20–140 mg/kg) ranged between 1.2 and 10.5%; the within-laboratory reproducibility (RSDR) ranged between 2.2 and 4.9%. The limit of determination was <20 mg/kg. Other feed additives did not interfere in the assay. The method showed ruggedness against changes in the composition of extraction solvent, eluent, and conditions for post-column reactions. In an interlaboratory study, 5 broiler feeds (4 positive, 1 blank) and 1 premixture were analyzed by 13 laboratories. The RSDr of the feedingstuffs (20–120 mg/kg) varied between 2.17 and 7.57%. The HORRAT ranged between 0.77 and 0.88, with recoveries between 82 and 104%. One laboratory detected small signals in the blank sample, calculated as 0.6 and 2.8 mg/kg. For the premixture, acceptable results for reproducibility could only be obtained after modification of the method: the RSDr was 4.42% and the HORRAT was 1.56 (12 laboratories).
Collapse
Affiliation(s)
- Alfred Thalmann
- State Agricultural Testing and Research Station Augustenberg (LUFA), Nesslerstr. 23, 76227 Karlsruhe, Germany
| | - Klaus Wagner
- State Agricultural Testing and Research Station Augustenberg (LUFA), Nesslerstr. 23, 76227 Karlsruhe, Germany
| | - Marinka Tomassen
- RIKILT–Institute of Food Safety, PO Box 230, 6700 AE, Wageningen, The Netherlands
| | - Jaap Driessen
- RIKILT–Institute of Food Safety, PO Box 230, 6700 AE, Wageningen, The Netherlands
| | - Jacob de Jong
- RIKILT–Institute of Food Safety, PO Box 230, 6700 AE, Wageningen, The Netherlands
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Träber N, Uhlmann K, Girardo S, Kesavan G, Wagner K, Friedrichs J, Goswami R, Bai K, Brand M, Werner C, Balzani D, Guck J. Polyacrylamide Bead Sensors for in vivo Quantification of Cell-Scale Stress in Zebrafish Development. Sci Rep 2019; 9:17031. [PMID: 31745109 PMCID: PMC6864055 DOI: 10.1038/s41598-019-53425-6] [Citation(s) in RCA: 31] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2019] [Accepted: 10/23/2019] [Indexed: 11/09/2022] Open
Abstract
Mechanical stress exerted and experienced by cells during tissue morphogenesis and organ formation plays an important role in embryonic development. While techniques to quantify mechanical stresses in vitro are available, few methods exist for studying stresses in living organisms. Here, we describe and characterize cell-like polyacrylamide (PAAm) bead sensors with well-defined elastic properties and size for in vivo quantification of cell-scale stresses. The beads were injected into developing zebrafish embryos and their deformations were computationally analyzed to delineate spatio-temporal local acting stresses. With this computational analysis-based cell-scale stress sensing (COMPAX) we are able to detect pulsatile pressure propagation in the developing neural rod potentially originating from polarized midline cell divisions and continuous tissue flow. COMPAX is expected to provide novel spatio-temporal insight into developmental processes at the local tissue level and to facilitate quantitative investigation and a better understanding of morphogenetic processes.
Collapse
Affiliation(s)
- N Träber
- Leibniz-Institut für Polymerforschung Dresden e. V., Hohe Str. 6, 01069, Dresden, Germany
- Biotechnology Center, Center for Molecular and Cellular Bioengineering, Technische Universität Dresden, Tatzberg 47/49, 01307, Dresden, Germany
| | - K Uhlmann
- Chair of Continuum Mechanics, Ruhr-Universität Bochum, Universitätsstraße 150, 44801, Bochum, Germany
| | - S Girardo
- Biotechnology Center, Center for Molecular and Cellular Bioengineering, Technische Universität Dresden, Tatzberg 47/49, 01307, Dresden, Germany
- Center for Regenerative Therapies Dresden, Center for Molecular and Cellular Bioengineering, Technische Universität Dresden, Fetscherstr. 105, 01307, Dresden, Germany
- Max Planck Institute for the Science of Light, Staudtstraße 2, 91058, Erlangen, Germany
| | - G Kesavan
- Center for Regenerative Therapies Dresden, Center for Molecular and Cellular Bioengineering, Technische Universität Dresden, Fetscherstr. 105, 01307, Dresden, Germany
| | - K Wagner
- Biotechnology Center, Center for Molecular and Cellular Bioengineering, Technische Universität Dresden, Tatzberg 47/49, 01307, Dresden, Germany
| | - J Friedrichs
- Leibniz-Institut für Polymerforschung Dresden e. V., Hohe Str. 6, 01069, Dresden, Germany
| | - R Goswami
- Center for Regenerative Therapies Dresden, Center for Molecular and Cellular Bioengineering, Technische Universität Dresden, Fetscherstr. 105, 01307, Dresden, Germany
- Max Planck Institute for the Science of Light, Staudtstraße 2, 91058, Erlangen, Germany
| | - K Bai
- Center for Regenerative Therapies Dresden, Center for Molecular and Cellular Bioengineering, Technische Universität Dresden, Fetscherstr. 105, 01307, Dresden, Germany
| | - M Brand
- Center for Regenerative Therapies Dresden, Center for Molecular and Cellular Bioengineering, Technische Universität Dresden, Fetscherstr. 105, 01307, Dresden, Germany
| | - C Werner
- Leibniz-Institut für Polymerforschung Dresden e. V., Hohe Str. 6, 01069, Dresden, Germany
| | - D Balzani
- Chair of Continuum Mechanics, Ruhr-Universität Bochum, Universitätsstraße 150, 44801, Bochum, Germany.
| | - J Guck
- Biotechnology Center, Center for Molecular and Cellular Bioengineering, Technische Universität Dresden, Tatzberg 47/49, 01307, Dresden, Germany.
- Max Planck Institute for the Science of Light, Staudtstraße 2, 91058, Erlangen, Germany.
| |
Collapse
|
34
|
Wagner K, Kunz K, Piller T, Tascher G, Hölper S, Stehmeier P, Keiten-Schmitz J, Schick M, Keller U, Müller S. The SUMO Isopeptidase SENP6 Functions as a Rheostat of Chromatin Residency in Genome Maintenance and Chromosome Dynamics. Cell Rep 2019; 29:480-494.e5. [PMID: 31597105 DOI: 10.1016/j.celrep.2019.08.106] [Citation(s) in RCA: 33] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2019] [Revised: 07/21/2019] [Accepted: 08/29/2019] [Indexed: 11/20/2022] Open
Abstract
Signaling by the ubiquitin-related SUMO pathway relies on coordinated conjugation and deconjugation events. SUMO-specific deconjugating enzymes counterbalance SUMOylation, but comprehensive insight into their substrate specificity and regulation is missing. By characterizing SENP6, we define an N-terminal multi-SIM domain as a critical determinant in targeting SENP6 to SUMO chains. Proteomic profiling reveals a network of SENP6 functions at the crossroads of chromatin organization and DNA damage response (DDR). SENP6 acts as a SUMO eraser at telomeric and centromeric chromatin domains and determines the SUMOylation status and chromatin association of the cohesin complex. Importantly, SENP6 is part of the hPSO4/PRP19 complex that drives ATR-Chk1 activation. SENP6 deficiency impairs chromatin association of the ATR cofactor ATRIP, thereby compromising the activation of Chk1 signaling in response to aphidicolin-induced replicative stress and sensitizing cells to DNA damage. We propose a general role of SENP6 in orchestrating chromatin dynamics and genome stability networks by balancing chromatin residency of protein complexes.
Collapse
Affiliation(s)
- Kristina Wagner
- Institute of Biochemistry II, Faculty of Medicine, Goethe University, Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - Kathrin Kunz
- Institute of Biochemistry II, Faculty of Medicine, Goethe University, Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - Tanja Piller
- Institute of Biochemistry II, Faculty of Medicine, Goethe University, Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - Georg Tascher
- Institute of Biochemistry II, Faculty of Medicine, Goethe University, Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - Soraya Hölper
- Institute of Biochemistry II, Faculty of Medicine, Goethe University, Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - Per Stehmeier
- Institute of Biochemistry II, Faculty of Medicine, Goethe University, Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - Jan Keiten-Schmitz
- Institute of Biochemistry II, Faculty of Medicine, Goethe University, Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
| | - Markus Schick
- Internal Medicine III, School of Medicine, Technische Universität München, Ismaninger Strasse 22, 81675 Munich, Germany; Department of Hematology, Oncology and Tumor Immunology (Campus Benjamin Franklin), Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany
| | - Ulrich Keller
- Internal Medicine III, School of Medicine, Technische Universität München, Ismaninger Strasse 22, 81675 Munich, Germany; Department of Hematology, Oncology and Tumor Immunology (Campus Benjamin Franklin), Charité Universitätsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany; German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
| | - Stefan Müller
- Institute of Biochemistry II, Faculty of Medicine, Goethe University, Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
| |
Collapse
|
35
|
Wagner K, Cripe L, Eagle M, Muntoni F, Niks E, Phan H, Straub V, Hu X, Antonijevic I, Berry S, Quintana M, Lake S, Panzara M. EP.83Design of a Phase 2/3 randomized controlled trial of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy amenable to exon 51 skipping. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.489] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
36
|
LoRusso S, Johnson N, McDermott M, Eichinger K, Butterfield R, Higgs K, Lewis L, Mul K, Van Engelen B, Sacconi S, Sansone V, Carraro E, Shieh P, Wagner K, Wang L, Statland J, Tawil R, the ReSolve Investigators. P.46Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, multi-center prospective study. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
Thangarajh M, Kaat A, Hardy K, Wagner K. P.279Pragmatic cognitive and psychosocial health monitoring in clinical practice in Duchenne muscular dystrophy. Neuromuscul Disord 2019. [DOI: 10.1016/j.nmd.2019.06.393] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
38
|
Abstract
OBJECTIVE To examine trends and variations in billed and paid amounts for preventive dental procedures by race/ethnicity, age, and sex in Wisconsin dental Medicaid. METHODS We analyzed data from the 2001 to 2013 Wisconsin Medicaid claims database for preventive dental procedures for children and adults. Billed and paid amounts for preventive dental procedures were aggregated over a visit and adjusted for inflation based on the Medical Care Consumer Price Index produced by the Bureau of Labor Statistics for 2013. Quantile regression was used to examine the trends over time and the effect of patient demographics. RESULT At the 50th and 75th percentiles, the overall billed amounts for preventive dental procedures were $84.97 and $105.53, and the paid amounts were $35.80 and $41.66, respectively. At the 75th percentile, there was a $2.24 increase per year in the billed amount and a $26.88 overall increase from 2001 to 2013. In the paid amount, there was a $1.34 decrease per year for an overall $16.07 decrease from 2001 to 2013. Billed and paid claims for racial/ethnic minority enrollees were $1 to $3 higher per visit at the 75th percentile when compared with those of Whites. Regarding the billed:paid ratio, White, African American, and Hispanic enrollees had values of 50% to 52%, whereas American Indians had the lowest value at 47.7%. At the 75th percentile, children aged 10 to 19 y had significantly higher billed ($26.73) and paid ($9.92) amounts than did adults aged 20 to 69 y. CONCLUSION The billed amount increased over time, and the paid amount decreased after adjustment for inflation. In addition, there was a wide gap between billed and paid amounts over time. KNOWLEDGE TRANSFER STATEMENT This study highlights clear differences between paid and billed amounts in Wisconsin dental Medicaid. The financial health of dental practices is dependent on appropriate reimbursement for dental services provided; thus, information of this nature could serve as a proxy performance measure for access to preventive dental care. Findings from this study could be used by policy makers and dental Medicaid program managers to develop outcome metrics to improve access to preventive dental services.
Collapse
Affiliation(s)
- K. Wagner
- Department of Economics, College of Business Administration, Marquette University, Milwaukee, WI, USA
| | - A. Szabo
- Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI, USA
| | - C. Zheng
- Joseph. J. Zilber School of Public Health, University of Wisconsin–Milwaukee, Milwaukee, WI, USA
| | - E. Okunseri
- Department of Clinical Services, School of Dentistry, Marquette University, Milwaukee, WI, USA
| | - C. Okunseri
- Department of Clinical Services, School of Dentistry, Marquette University, Milwaukee, WI, USA
| |
Collapse
|
39
|
Morales JC, Mustill AJ, Ribas I, Davies MB, Reiners A, Bauer FF, Kossakowski D, Herrero E, Rodríguez E, López-González MJ, Rodríguez-López C, Béjar VJS, González-Cuesta L, Luque R, Pallé E, Perger M, Baroch D, Johansen A, Klahr H, Mordasini C, Anglada-Escudé G, Caballero JA, Cortés-Contreras M, Dreizler S, Lafarga M, Nagel E, Passegger VM, Reffert S, Rosich A, Schweitzer A, Tal-Or L, Trifonov T, Zechmeister M, Quirrenbach A, Amado PJ, Guenther EW, Hagen HJ, Henning T, Jeffers SV, Kaminski A, Kürster M, Montes D, Seifert W, Abellán FJ, Abril M, Aceituno J, Aceituno FJ, Alonso-Floriano FJ, Ammler-von Eiff M, Antona R, Arroyo-Torres B, Azzaro M, Barrado D, Becerril-Jarque S, Benítez D, Berdiñas ZM, Bergond G, Brinkmöller M, Del Burgo C, Burn R, Calvo-Ortega R, Cano J, Cárdenas MC, Guillén CC, Carro J, Casal E, Casanova V, Casasayas-Barris N, Chaturvedi P, Cifuentes C, Claret A, Colomé J, Czesla S, Díez-Alonso E, Dorda R, Emsenhuber A, Fernández M, Fernández-Martín A, Ferro IM, Fuhrmeister B, Galadí-Enríquez D, Cava IG, Vargas MLG, Garcia-Piquer A, Gesa L, González-Álvarez E, Hernández JIG, González-Peinado R, Guàrdia J, Guijarro A, de Guindos E, Hatzes AP, Hauschildt PH, Hedrosa RP, Hermelo I, Arabi RH, Otero FH, Hintz D, Holgado G, Huber A, Huke P, Johnson EN, de Juan E, Kehr M, Kemmer J, Kim M, Klüter J, Klutsch A, Labarga F, Labiche N, Lalitha S, Lampón M, Lara LM, Launhardt R, Lázaro FJ, Lizon JL, Llamas M, Lodieu N, López Del Fresno M, Salas JFL, López-Santiago J, Madinabeitia HM, Mall U, Mancini L, Mandel H, Marfil E, Molina JAM, Martín EL, Martín-Fernández P, Martín-Ruiz S, Martínez-Rodríguez H, Marvin CJ, Mirabet E, Moya A, Naranjo V, Nelson RP, Nortmann L, Nowak G, Ofir A, Pascual J, Pavlov A, Pedraz S, Medialdea DP, Pérez-Calpena A, Perryman MAC, Rabaza O, Ballesta AR, Rebolo R, Redondo P, Rix HW, Rodler F, Trinidad AR, Sabotta S, Sadegi S, Salz M, Sánchez-Blanco E, Carrasco MAS, Sánchez-López A, Sanz-Forcada J, Sarkis P, Sarmiento LF, Schäfer S, Schlecker M, Schmitt JHMM, Schöfer P, Solano E, Sota A, Stahl O, Stock S, Stuber T, Stürmer J, Suárez JC, Tabernero HM, Tulloch SM, Veredas G, Vico-Linares JI, Vilardell F, Wagner K, Winkler J, Wolthoff V, Yan F, Osorio MRZ. A giant exoplanet orbiting a very-low-mass star challenges planet formation models. Science 2019; 365:1441-1445. [PMID: 31604272 DOI: 10.1126/science.aax3198] [Citation(s) in RCA: 50] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2019] [Accepted: 08/27/2019] [Indexed: 01/03/2023]
Abstract
Surveys have shown that super-Earth and Neptune-mass exoplanets are more frequent than gas giants around low-mass stars, as predicted by the core accretion theory of planet formation. We report the discovery of a giant planet around the very-low-mass star GJ 3512, as determined by optical and near-infrared radial-velocity observations. The planet has a minimum mass of 0.46 Jupiter masses, very high for such a small host star, and an eccentric 204-day orbit. Dynamical models show that the high eccentricity is most likely due to planet-planet interactions. We use simulations to demonstrate that the GJ 3512 planetary system challenges generally accepted formation theories, and that it puts constraints on the planet accretion and migration rates. Disk instabilities may be more efficient in forming planets than previously thought.
Collapse
Affiliation(s)
- J C Morales
- Institut de Ciències de l'Espai (Consejo Superior de Investigaciones Científicas), Campus Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain. .,Institut d'Estudis Espacials de Catalunya, E-08034 Barcelona, Spain
| | - A J Mustill
- Lund Observatory, Department of Astronomy and Theoretical Physics, Lund University, Box 43, SE-221 00 Lund, Sweden
| | - I Ribas
- Institut de Ciències de l'Espai (Consejo Superior de Investigaciones Científicas), Campus Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.,Institut d'Estudis Espacials de Catalunya, E-08034 Barcelona, Spain
| | - M B Davies
- Lund Observatory, Department of Astronomy and Theoretical Physics, Lund University, Box 43, SE-221 00 Lund, Sweden
| | - A Reiners
- Institut für Astrophysik, Georg-August-Universität, D-37077 Göttingen, Germany
| | - F F Bauer
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - D Kossakowski
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany
| | - E Herrero
- Institut de Ciències de l'Espai (Consejo Superior de Investigaciones Científicas), Campus Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.,Institut d'Estudis Espacials de Catalunya, E-08034 Barcelona, Spain
| | - E Rodríguez
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - M J López-González
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - C Rodríguez-López
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - V J S Béjar
- Instituto de Astrofísica de Canarias, E-38205 La Laguna, Tenerife, Spain.,Departamento de Astrofísica, Universidad de La Laguna, E-38206 La Laguna, Tenerife, Spain
| | - L González-Cuesta
- Instituto de Astrofísica de Canarias, E-38205 La Laguna, Tenerife, Spain.,Departamento de Astrofísica, Universidad de La Laguna, E-38206 La Laguna, Tenerife, Spain
| | - R Luque
- Instituto de Astrofísica de Canarias, E-38205 La Laguna, Tenerife, Spain.,Departamento de Astrofísica, Universidad de La Laguna, E-38206 La Laguna, Tenerife, Spain
| | - E Pallé
- Instituto de Astrofísica de Canarias, E-38205 La Laguna, Tenerife, Spain.,Departamento de Astrofísica, Universidad de La Laguna, E-38206 La Laguna, Tenerife, Spain
| | - M Perger
- Institut de Ciències de l'Espai (Consejo Superior de Investigaciones Científicas), Campus Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.,Institut d'Estudis Espacials de Catalunya, E-08034 Barcelona, Spain
| | - D Baroch
- Institut de Ciències de l'Espai (Consejo Superior de Investigaciones Científicas), Campus Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.,Institut d'Estudis Espacials de Catalunya, E-08034 Barcelona, Spain
| | - A Johansen
- Lund Observatory, Department of Astronomy and Theoretical Physics, Lund University, Box 43, SE-221 00 Lund, Sweden
| | - H Klahr
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany
| | - C Mordasini
- Physikalisches Institut, Universität Bern, CH-3012 Bern, Switzerland
| | - G Anglada-Escudé
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain.,School of Physics and Astronomy, Queen Mary University of London, London E1 4NS, UK
| | - J A Caballero
- Centro de Astrobiología (Consejo Superior de Investigaciones Científicas-Instituto Nacional de Técnica Aeroespacial), European Space Astronomy Centre Campus (European Space Agency), E-28692 Villanueva de la Cañada, Spain
| | - M Cortés-Contreras
- Centro de Astrobiología (Consejo Superior de Investigaciones Científicas-Instituto Nacional de Técnica Aeroespacial), European Space Astronomy Centre Campus (European Space Agency), E-28692 Villanueva de la Cañada, Spain
| | - S Dreizler
- Institut für Astrophysik, Georg-August-Universität, D-37077 Göttingen, Germany
| | - M Lafarga
- Institut de Ciències de l'Espai (Consejo Superior de Investigaciones Científicas), Campus Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.,Institut d'Estudis Espacials de Catalunya, E-08034 Barcelona, Spain
| | - E Nagel
- Hamburger Sternwarte, Universität Hamburg, D-21029 Hamburg, Germany
| | - V M Passegger
- Hamburger Sternwarte, Universität Hamburg, D-21029 Hamburg, Germany
| | - S Reffert
- Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, D-69117 Heidelberg, Germany
| | - A Rosich
- Institut de Ciències de l'Espai (Consejo Superior de Investigaciones Científicas), Campus Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.,Institut d'Estudis Espacials de Catalunya, E-08034 Barcelona, Spain
| | - A Schweitzer
- Hamburger Sternwarte, Universität Hamburg, D-21029 Hamburg, Germany
| | - L Tal-Or
- Institut für Astrophysik, Georg-August-Universität, D-37077 Göttingen, Germany.,Department of Geophysics, Raymond and Beverly Sackler Faculty of Exact Sciences, Tel Aviv University, Tel Aviv 6997801, Israel
| | - T Trifonov
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany
| | - M Zechmeister
- Institut für Astrophysik, Georg-August-Universität, D-37077 Göttingen, Germany
| | - A Quirrenbach
- Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, D-69117 Heidelberg, Germany
| | - P J Amado
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - E W Guenther
- Thüringer Landessternwarte Tautenburg, D-07778 Tautenburg, Germany
| | - H-J Hagen
- Hamburger Sternwarte, Universität Hamburg, D-21029 Hamburg, Germany
| | - T Henning
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany
| | - S V Jeffers
- Institut für Astrophysik, Georg-August-Universität, D-37077 Göttingen, Germany
| | - A Kaminski
- Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, D-69117 Heidelberg, Germany
| | - M Kürster
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany
| | - D Montes
- Departamento de Física de la Tierra y Astrofísica, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Instituto de Física de Partículas y del Cosmos, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - W Seifert
- Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, D-69117 Heidelberg, Germany
| | - F J Abellán
- Departamento de Física de la Tierra y Astrofísica, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Instituto de Física de Partículas y del Cosmos, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Departamento de Astronomía y Astrofísica, Universidad de Valencia, E-46100 Burjassot, Spain
| | - M Abril
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - J Aceituno
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain.,Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - F J Aceituno
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - F J Alonso-Floriano
- Departamento de Física de la Tierra y Astrofísica, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Instituto de Física de Partículas y del Cosmos, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Leiden Observatory, Leiden University, 2300 RA Leiden, Netherlands
| | - M Ammler-von Eiff
- Thüringer Landessternwarte Tautenburg, D-07778 Tautenburg, Germany.,Max Planck Institute for Solar System Research, D-37077 Göttingen, Germany
| | - R Antona
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - B Arroyo-Torres
- Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - M Azzaro
- Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - D Barrado
- Centro de Astrobiología (Consejo Superior de Investigaciones Científicas-Instituto Nacional de Técnica Aeroespacial), European Space Astronomy Centre Campus (European Space Agency), E-28692 Villanueva de la Cañada, Spain
| | - S Becerril-Jarque
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - D Benítez
- Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - Z M Berdiñas
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain.,Departamento de Astronomía, Universidad de Chile, Camino El Observatorio, 1515 Las Condes, Santiago, Chile
| | - G Bergond
- Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - M Brinkmöller
- Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, D-69117 Heidelberg, Germany
| | - C Del Burgo
- Instituto Nacional de Astrofísica, Óptica y Electrónica, Santa María Tonantzintla, Puebla, Mexico
| | - R Burn
- Physikalisches Institut, Universität Bern, CH-3012 Bern, Switzerland
| | - R Calvo-Ortega
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - J Cano
- Departamento de Física de la Tierra y Astrofísica, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Instituto de Física de Partículas y del Cosmos, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - M C Cárdenas
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany
| | - C Cardona Guillén
- Instituto de Astrofísica de Canarias, E-38205 La Laguna, Tenerife, Spain.,Departamento de Astrofísica, Universidad de La Laguna, E-38206 La Laguna, Tenerife, Spain
| | - J Carro
- Departamento de Física de la Tierra y Astrofísica, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Instituto de Física de Partículas y del Cosmos, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - E Casal
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - V Casanova
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - N Casasayas-Barris
- Instituto de Astrofísica de Canarias, E-38205 La Laguna, Tenerife, Spain.,Departamento de Astrofísica, Universidad de La Laguna, E-38206 La Laguna, Tenerife, Spain
| | - P Chaturvedi
- Thüringer Landessternwarte Tautenburg, D-07778 Tautenburg, Germany
| | - C Cifuentes
- Centro de Astrobiología (Consejo Superior de Investigaciones Científicas-Instituto Nacional de Técnica Aeroespacial), European Space Astronomy Centre Campus (European Space Agency), E-28692 Villanueva de la Cañada, Spain.,Departamento de Física de la Tierra y Astrofísica, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Instituto de Física de Partículas y del Cosmos, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - A Claret
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - J Colomé
- Institut de Ciències de l'Espai (Consejo Superior de Investigaciones Científicas), Campus Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.,Institut d'Estudis Espacials de Catalunya, E-08034 Barcelona, Spain
| | - S Czesla
- Hamburger Sternwarte, Universität Hamburg, D-21029 Hamburg, Germany
| | - E Díez-Alonso
- Departamento de Física de la Tierra y Astrofísica, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Instituto de Física de Partículas y del Cosmos, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Departamento de Explotación y Prospeción de Minas, Escuela de Minas, Energía y Materiales, Universidad de Oviedo, E-33003 Oviedo, Asturias, Spain
| | - R Dorda
- Instituto de Astrofísica de Canarias, E-38205 La Laguna, Tenerife, Spain.,Departamento de Astrofísica, Universidad de La Laguna, E-38206 La Laguna, Tenerife, Spain.,Departamento de Física de la Tierra y Astrofísica, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Instituto de Física de Partículas y del Cosmos, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - A Emsenhuber
- Lunar and Planetary Laboratory, University of Arizona, Tucson, AZ 85721, USA
| | - M Fernández
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - A Fernández-Martín
- Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - I M Ferro
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - B Fuhrmeister
- Hamburger Sternwarte, Universität Hamburg, D-21029 Hamburg, Germany
| | - D Galadí-Enríquez
- Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - I Gallardo Cava
- Departamento de Física de la Tierra y Astrofísica, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Instituto de Física de Partículas y del Cosmos, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Observatorio Astronómico Nacional (OAN-Instituto Geográfico Nacional), E-28803 Alcalá de Henares, Spain
| | | | - A Garcia-Piquer
- Institut de Ciències de l'Espai (Consejo Superior de Investigaciones Científicas), Campus Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.,Institut d'Estudis Espacials de Catalunya, E-08034 Barcelona, Spain
| | - L Gesa
- Institut de Ciències de l'Espai (Consejo Superior de Investigaciones Científicas), Campus Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.,Institut d'Estudis Espacials de Catalunya, E-08034 Barcelona, Spain
| | - E González-Álvarez
- Centro de Astrobiología (Consejo Superior de Investigaciones Científicas-Instituto Nacional de Técnica Aeroespacial), E-28850 Torrejón de Ardoz, Madrid, Spain
| | - J I González Hernández
- Instituto de Astrofísica de Canarias, E-38205 La Laguna, Tenerife, Spain.,Departamento de Astrofísica, Universidad de La Laguna, E-38206 La Laguna, Tenerife, Spain
| | - R González-Peinado
- Departamento de Física de la Tierra y Astrofísica, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Instituto de Física de Partículas y del Cosmos, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - J Guàrdia
- Institut de Ciències de l'Espai (Consejo Superior de Investigaciones Científicas), Campus Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.,Institut d'Estudis Espacials de Catalunya, E-08034 Barcelona, Spain
| | - A Guijarro
- Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - E de Guindos
- Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - A P Hatzes
- Thüringer Landessternwarte Tautenburg, D-07778 Tautenburg, Germany
| | - P H Hauschildt
- Hamburger Sternwarte, Universität Hamburg, D-21029 Hamburg, Germany
| | - R P Hedrosa
- Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - I Hermelo
- Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - R Hernández Arabi
- Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - F Hernández Otero
- Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - D Hintz
- Hamburger Sternwarte, Universität Hamburg, D-21029 Hamburg, Germany
| | - G Holgado
- Instituto de Astrofísica de Canarias, E-38205 La Laguna, Tenerife, Spain.,Departamento de Astrofísica, Universidad de La Laguna, E-38206 La Laguna, Tenerife, Spain.,Departamento de Física de la Tierra y Astrofísica, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Instituto de Física de Partículas y del Cosmos, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - A Huber
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany
| | - P Huke
- Institut für Astrophysik, Georg-August-Universität, D-37077 Göttingen, Germany
| | - E N Johnson
- Institut für Astrophysik, Georg-August-Universität, D-37077 Göttingen, Germany
| | - E de Juan
- Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - M Kehr
- Thüringer Landessternwarte Tautenburg, D-07778 Tautenburg, Germany
| | - J Kemmer
- Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, D-69117 Heidelberg, Germany
| | - M Kim
- Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, D-69117 Heidelberg, Germany.,Institut für Theoretische Physik und Astrophysik, D-24118 Kiel, Germany
| | - J Klüter
- Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, D-69117 Heidelberg, Germany.,Zentrum für Astronomie der Universität Heidelberg, Astronomisches Rechen-Institut, D-69120 Heidelberg, Germany
| | - A Klutsch
- Departamento de Física de la Tierra y Astrofísica, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Instituto de Física de Partículas y del Cosmos, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Institut für Astronomie und Astrophysik, Eberhard Karls Universität, D-72076 Tübingen, Germany
| | - F Labarga
- Departamento de Física de la Tierra y Astrofísica, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Instituto de Física de Partículas y del Cosmos, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - N Labiche
- Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, D-69117 Heidelberg, Germany
| | - S Lalitha
- Institut für Astrophysik, Georg-August-Universität, D-37077 Göttingen, Germany
| | - M Lampón
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - L M Lara
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - R Launhardt
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany
| | - F J Lázaro
- Departamento de Física de la Tierra y Astrofísica, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Instituto de Física de Partículas y del Cosmos, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - J-L Lizon
- European Organisation for Astronomical Research in the Southern Hemisphere, D-85748 Garching bei München, Germany
| | - M Llamas
- Departamento de Física de la Tierra y Astrofísica, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Instituto de Física de Partículas y del Cosmos, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - N Lodieu
- Instituto de Astrofísica de Canarias, E-38205 La Laguna, Tenerife, Spain.,Departamento de Astrofísica, Universidad de La Laguna, E-38206 La Laguna, Tenerife, Spain
| | - M López Del Fresno
- Centro de Astrobiología (Consejo Superior de Investigaciones Científicas-Instituto Nacional de Técnica Aeroespacial), European Space Astronomy Centre Campus (European Space Agency), E-28692 Villanueva de la Cañada, Spain
| | - J F López Salas
- Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - J López-Santiago
- Departamento de Física de la Tierra y Astrofísica, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Instituto de Física de Partículas y del Cosmos, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Department of Signal Theory and Communications, Universidad Carlos III de Madrid, E-28911 Leganés, Madrid, Spain.,Gregorio Marañón Health Research Institute, E-28007 Madrid, Spain
| | - H Magán Madinabeitia
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain.,Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - U Mall
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany
| | - L Mancini
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany.,Department of Physics, University of Rome Tor Vergata, I-00133 Roma, Italy.,Istituto Nazionale di Astrofisica-Osservatorio Astrofisico di Torino, I-10025 Pino Torinese, Italy.,International Institute for Advanced Scientific Studies, I-84019 Vietri sul Mare (SA), Italy
| | - H Mandel
- Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, D-69117 Heidelberg, Germany
| | - E Marfil
- Departamento de Física de la Tierra y Astrofísica, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Instituto de Física de Partículas y del Cosmos, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain
| | - J A Marín Molina
- Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - E L Martín
- Centro de Astrobiología (Consejo Superior de Investigaciones Científicas-Instituto Nacional de Técnica Aeroespacial), E-28850 Torrejón de Ardoz, Madrid, Spain
| | - P Martín-Fernández
- Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - S Martín-Ruiz
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - H Martínez-Rodríguez
- Departamento de Física de la Tierra y Astrofísica, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Instituto de Física de Partículas y del Cosmos, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, E-28040 Madrid, Spain.,Department of Physics and Astronomy and Pittsburgh Particle Physics, Astrophysics and Cosmology Center, University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - C J Marvin
- Institut für Astrophysik, Georg-August-Universität, D-37077 Göttingen, Germany
| | - E Mirabet
- Institut de Ciències de l'Espai (Consejo Superior de Investigaciones Científicas), Campus Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.,Institut d'Estudis Espacials de Catalunya, E-08034 Barcelona, Spain.,Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - A Moya
- Centro de Astrobiología (Consejo Superior de Investigaciones Científicas-Instituto Nacional de Técnica Aeroespacial), European Space Astronomy Centre Campus (European Space Agency), E-28692 Villanueva de la Cañada, Spain.,School of Physics and Astronomy, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.,Stellar Astrophysics Centre, Department of Physics and Astronomy, Aarhus University, DK-8000 Aarhus C, Denmark
| | - V Naranjo
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany
| | - R P Nelson
- School of Physics and Astronomy, Queen Mary University of London, London E1 4NS, UK
| | - L Nortmann
- Instituto de Astrofísica de Canarias, E-38205 La Laguna, Tenerife, Spain.,Departamento de Astrofísica, Universidad de La Laguna, E-38206 La Laguna, Tenerife, Spain
| | - G Nowak
- Instituto de Astrofísica de Canarias, E-38205 La Laguna, Tenerife, Spain.,Departamento de Astrofísica, Universidad de La Laguna, E-38206 La Laguna, Tenerife, Spain
| | - A Ofir
- Department of Earth and Planetary Sciences, Weizmann Institute of Science, Rehovot 76100, Israel
| | - J Pascual
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - A Pavlov
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany
| | - S Pedraz
- Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - D Pérez Medialdea
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | | | - M A C Perryman
- School of Physics, University College Dublin, Belfield Downs, Dublin D14 YH57, Ireland
| | - O Rabaza
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain.,Dpto. Ingeniería Civil, Universidad de Granada, E-18071 Granada, Spain
| | - A Ramón Ballesta
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - R Rebolo
- Instituto de Astrofísica de Canarias, E-38205 La Laguna, Tenerife, Spain.,Departamento de Astrofísica, Universidad de La Laguna, E-38206 La Laguna, Tenerife, Spain
| | - P Redondo
- Instituto de Astrofísica de Canarias, E-38205 La Laguna, Tenerife, Spain
| | - H-W Rix
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany
| | - F Rodler
- Institut de Ciències de l'Espai (Consejo Superior de Investigaciones Científicas), Campus Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.,Institut d'Estudis Espacials de Catalunya, E-08034 Barcelona, Spain.,European Southern Observatory, Vitacura, Casilla 19001, Santiago de Chile
| | - A Rodríguez Trinidad
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - S Sabotta
- Thüringer Landessternwarte Tautenburg, D-07778 Tautenburg, Germany
| | - S Sadegi
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany.,Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, D-69117 Heidelberg, Germany
| | - M Salz
- Hamburger Sternwarte, Universität Hamburg, D-21029 Hamburg, Germany
| | | | - M A Sánchez Carrasco
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - A Sánchez-López
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - J Sanz-Forcada
- Centro de Astrobiología (Consejo Superior de Investigaciones Científicas-Instituto Nacional de Técnica Aeroespacial), European Space Astronomy Centre Campus (European Space Agency), E-28692 Villanueva de la Cañada, Spain
| | - P Sarkis
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany
| | - L F Sarmiento
- Institut für Astrophysik, Georg-August-Universität, D-37077 Göttingen, Germany
| | - S Schäfer
- Institut für Astrophysik, Georg-August-Universität, D-37077 Göttingen, Germany
| | - M Schlecker
- Max-Planck-Institut für Astronomie, D-69117 Heidelberg, Germany
| | - J H M M Schmitt
- Hamburger Sternwarte, Universität Hamburg, D-21029 Hamburg, Germany
| | - P Schöfer
- Institut für Astrophysik, Georg-August-Universität, D-37077 Göttingen, Germany
| | - E Solano
- Centro de Astrobiología (Consejo Superior de Investigaciones Científicas-Instituto Nacional de Técnica Aeroespacial), European Space Astronomy Centre Campus (European Space Agency), E-28692 Villanueva de la Cañada, Spain
| | - A Sota
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain
| | - O Stahl
- Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, D-69117 Heidelberg, Germany
| | - S Stock
- Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, D-69117 Heidelberg, Germany
| | - T Stuber
- Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, D-69117 Heidelberg, Germany
| | - J Stürmer
- Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, D-69117 Heidelberg, Germany.,Department of Astronomy and Astrophysics, University of Chicago, Chicago, IL 60637, USA
| | - J C Suárez
- Instituto de Astrofísica de Andalucía (Consejo Superior de Investigaciones Científicas), E-18008 Granada, Spain.,Dpto. Física Teórica y del Cosmos, Universidad de Granada, E-18071 Granada, Spain
| | - H M Tabernero
- Centro de Astrobiología (Consejo Superior de Investigaciones Científicas-Instituto Nacional de Técnica Aeroespacial), E-28850 Torrejón de Ardoz, Madrid, Spain
| | - S M Tulloch
- Department of Physics and Astronomy, University of Sheffield, Sheffield S3 7RH, UK
| | - G Veredas
- Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, D-69117 Heidelberg, Germany
| | - J I Vico-Linares
- Centro Astronómico Hispano-Alemán (Consejo Superior de Investigaciones Científicas-Max-Planck-Gesellschaft), Observatorio Astronómico de Calar Alto, Sierra de los Filabres, E-04550 Gérgal, Almería, Spain
| | - F Vilardell
- Institut de Ciències de l'Espai (Consejo Superior de Investigaciones Científicas), Campus Universitat Autònoma de Barcelona, E-08193 Bellaterra, Spain.,Institut d'Estudis Espacials de Catalunya, E-08034 Barcelona, Spain
| | - K Wagner
- Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, D-69117 Heidelberg, Germany
| | - J Winkler
- Thüringer Landessternwarte Tautenburg, D-07778 Tautenburg, Germany
| | - V Wolthoff
- Landessternwarte, Zentrum für Astronomie der Universität Heidelberg, D-69117 Heidelberg, Germany
| | - F Yan
- Institut für Astrophysik, Georg-August-Universität, D-37077 Göttingen, Germany
| | - M R Zapatero Osorio
- Centro de Astrobiología (Consejo Superior de Investigaciones Científicas-Instituto Nacional de Técnica Aeroespacial), E-28850 Torrejón de Ardoz, Madrid, Spain
| |
Collapse
|
40
|
Benezeder T, Painsi C, Wagner K, Lange-Asschenfeldt B, Wolf P. 1007 Dithranol-treated psoriasis lesions show unique early changes in gene expression profile. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.1083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
41
|
Wagner K, Springer B, Pires V, Keller P. High-throughput screening of bacterial pathogens in clinical specimens using 16S rDNA qPCR and fragment analysis. Diagn Microbiol Infect Dis 2019; 93:287-292. [DOI: 10.1016/j.diagmicrobio.2018.11.006] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Revised: 11/09/2018] [Accepted: 11/12/2018] [Indexed: 11/29/2022]
|
42
|
Schultheiss K, Verba R, Wehrmann F, Wagner K, Körber L, Hula T, Hache T, Kákay A, Awad AA, Tiberkevich V, Slavin AN, Fassbender J, Schultheiss H. Excitation of Whispering Gallery Magnons in a Magnetic Vortex. Phys Rev Lett 2019; 122:097202. [PMID: 30932517 DOI: 10.1103/physrevlett.122.097202] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/02/2018] [Indexed: 06/09/2023]
Abstract
We present the generation of whispering gallery magnons with unprecedented high wave vectors via nonlinear 3-magnon scattering in a μm-sized magnetic Ni_{81}Fe_{19} disc which is in the vortex state. These modes exhibit a strong localization at the perimeter of the disc and practically zero amplitude in an extended area around the vortex core. They originate from the splitting of the fundamental radial magnon modes, which can be resonantly excited in a vortex texture by an out-of-plane microwave field. We shed light on the basics of this nonlinear scattering mechanism from an experimental and theoretical point of view. Using Brillouin light scattering microscopy, we investigated the frequency and power dependence of the 3-magnon splitting. The spatially resolved mode profiles give evidence for the localization at the boundaries of the disc and allow for a direct determination of the modes wave number.
Collapse
Affiliation(s)
- K Schultheiss
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Ion Beam Physics and Materials Research, Bautzner Landstraße 400, 01328 Dresden, Germany
| | - R Verba
- Institute of Magnetism, National Academy of Sciences of Ukraine, Kyiv 03680, Ukraine
| | - F Wehrmann
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Ion Beam Physics and Materials Research, Bautzner Landstraße 400, 01328 Dresden, Germany
| | - K Wagner
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Ion Beam Physics and Materials Research, Bautzner Landstraße 400, 01328 Dresden, Germany
- Technische Universität Dresden, 01062 Dresden, Germany
| | - L Körber
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Ion Beam Physics and Materials Research, Bautzner Landstraße 400, 01328 Dresden, Germany
- Technische Universität Dresden, 01062 Dresden, Germany
| | - T Hula
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Ion Beam Physics and Materials Research, Bautzner Landstraße 400, 01328 Dresden, Germany
- Westsächsische Hochschule Zwickau, 08056 Zwickau, Germany
| | - T Hache
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Ion Beam Physics and Materials Research, Bautzner Landstraße 400, 01328 Dresden, Germany
- Institut für Physik, Technische Universität Chemnitz, 09107 Chemnitz, Germany
| | - A Kákay
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Ion Beam Physics and Materials Research, Bautzner Landstraße 400, 01328 Dresden, Germany
| | - A A Awad
- Department of Physics, University of Gothenburg, 412 96 Gothenburg, Sweden
| | - V Tiberkevich
- Department of Physics, Oakland University, Rochester, Michigan 48309, USA
| | - A N Slavin
- Department of Physics, Oakland University, Rochester, Michigan 48309, USA
| | - J Fassbender
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Ion Beam Physics and Materials Research, Bautzner Landstraße 400, 01328 Dresden, Germany
- Technische Universität Dresden, 01062 Dresden, Germany
| | - H Schultheiss
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Ion Beam Physics and Materials Research, Bautzner Landstraße 400, 01328 Dresden, Germany
- Technische Universität Dresden, 01062 Dresden, Germany
| |
Collapse
|
43
|
Sinn BV, Loibl S, Karn T, Untch M, Kunze CA, Weber KE, Treue D, Wagner K, Hanusch CA, Klauschen F, Fasching PA, Huober J, Zahm DM, Jackisch C, Thomalla J, Blohmer JU, van Mackelenbergh M, Rhiem K, Felder B, von Minckwitz G, Burchardi N, Schneeweiss A, Denkert C. Abstract PD5-05: Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd5-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
In the GeparNuevo trial, the PD-L1 inhibitor durvalumab increased the rate of pathologic complete response (pCR; ypT0 ypN0) in triple-negative breast cancer if treatment started in a two-week window before neoadjuvant taxane/anthracycline chemotherapy (61 % pCR vs. 41%; p = 0.048; Loibl et al. ASCO 2018). Overall, pCR rates increased only numerically from 53 % to 44 % (p = 0.281). Herein, we aimed to evaluate the predictive value of PD-L1 immunohistochemistry in pre-therapeutic core biopsies. In addition, we identified dynamics in gene expression using repeated biopsies.
Patients and Methods
174 patients were randomized to receive durvalumab or placebo with neoadjuvant chemotherapy. In the window part, 117 patients received a single dose of durvalumab (or placebo) before chemotherapy. Core biopsies were taken at three times: pre-treatment (“A”; N=174), after the window part (“B”; N=88) and after 12 weeks of nab-Paclitaxel (“C”; N=33). PD-L1 immunohistochemistry in A-biopsies (Ventana SP263 Assay) was recorded as percentage of cells with membranous staining in tumor cells and lymphocytes (TILs). We defined a tumor as PD-L1 high if ≥ 25 % of either compartment was stained. Ki-67 was stained on all available A, B and C biopsies (MIB-1, Dako, 1:100) and recorded as the percentage of tumor cells with nuclear staining. We profiled all available biopsies with targeted RNASeq using the HTG EdgeSeq platform (Oncology Biomarker panel, 2560 genes). Sequencing (IonTorrent S5) was successful in 162 A-, 79 B- and 31 C-biopsies.
Results
PD-L1 expression was high in 24 % of A-biopsies and was predictive for pCR in the complete cohort (OR 2.561; 1.183-5.554; p = 0.017). PD-L1 status of the TILs, but not of the tumor cells, was predictive (OR 1.313; 1.040-1.656; P= 0.022). The effect was not specific for durvalumab treatment. Higher levels of Ki-67 were predictive for pCR in B- biopsies in all patients (OR 1.399; 1.053-1.858; P =0.021) and in the placebo arm, but not in the durvalumab arm. Ki-67 levels in C-biopsies were not predictive; neither was the change in Ki-67 between pre-treatment and later time points (B vs. A or C vs. A).
In a differential mRNA expression analysis (A vs. B), we found seven differentially expressed genes after one dose of durvalumab. We observed strong effects on gene expression after taxane treatment (A vs. C), but no significant difference according to treatment. These genes were associated with biological processes involved in therapy response. The pre-treatment levels of 12 of 69 markedly differentially expressed genes were associated with worse response to chemotherapy.
Conclusion
In A-biopsies, PD-L1 in TILs was predictive for response, and in B-biopsies, Ki-67 was predictive, but neither marker could specifically predict response to durvalumab. We observed limited effects of a single half-dose of durvalumab on global gene expression, but could identify substantial differential expression after taxane treatment. The evaluation of gene expression dynamic offers a promising approach for the identification of resistance-associated markers.
The study was financially supported by AstraZeneca and Celgene
Citation Format: Sinn BV, Loibl S, Karn T, Untch M, Kunze CA, Weber KE, Treue D, Wagner K, Hanusch CA, Klauschen F, Fasching PA, Huober J, Zahm D-M, Jackisch C, Thomalla J, Blohmer J-U, van Mackelenbergh M, Rhiem K, Felder B, von Minckwitz G, Burchardi N, Schneeweiss A, Denkert C. Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD5-05.
Collapse
Affiliation(s)
- BV Sinn
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - S Loibl
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - T Karn
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - M Untch
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - CA Kunze
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - KE Weber
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - D Treue
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - K Wagner
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - CA Hanusch
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - F Klauschen
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - PA Fasching
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - J Huober
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - D-M Zahm
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - C Jackisch
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - J Thomalla
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - J-U Blohmer
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - M van Mackelenbergh
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - K Rhiem
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - B Felder
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - G von Minckwitz
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - N Burchardi
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - A Schneeweiss
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| | - C Denkert
- Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; German Breast Group, Neu-Isenburg, Germany; Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum, Frankfurt, Germany; HELIOS Klinikum, Berlin-Buch, Germany; Pathologie am Rotkreuzklinikum, München, Germany; Klinikum zum Roten Kreuz, München, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Universitätsfrauenklink, Brustzentrum, Ulm, Germany; SRH Wald-Klinikum, Gera, Germany; Sana Klinikum, Offenbach, Germany; Praxisklinik für Haematologie und Onkologie, Koblenz, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum, Kiel, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany
| |
Collapse
|
44
|
Schiffer M, Carls E, Wagner K, Engelbrecht B, Duerr D, Welz A, de la JM, Pfeifer A, Fleischmann K, Roell W. Transplantation of Cx43 Expressing Fibroblasts: An Option for Postinfarct Arrhythmia Prevention? Thorac Cardiovasc Surg 2019. [DOI: 10.1055/s-0039-1678988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- M. Schiffer
- Department of Cardiac Surgery, University Hospital Bonn, Bonn, Germany
| | - E. Carls
- Department of Cardiac Surgery, University Hospital Bonn, Bonn, Germany
| | - K. Wagner
- Department of Cardiac Surgery, University Hospital Bonn, Bonn, Germany
| | - B. Engelbrecht
- Department of Cardiac Surgery, University Hospital Bonn, Bonn, Germany
| | - D. Duerr
- Department of Cardiac Surgery, University Hospital Bonn, Bonn, Germany
| | - A. Welz
- Department of Cardiac Surgery, University Hospital Bonn, Bonn, Germany
| | - J. M. de la
- University of Zaragoza, Institute of Material Science of Aragón, Zaragoza, Spain
| | - A. Pfeifer
- Department of Pharmacology and Toxicology, University Bonn, Bonn, Germany
| | - K. Fleischmann
- Department of Physiology I, University Bonn, Bonn, Germany
| | - W. Roell
- Department of Cardiac Surgery, University Hospital Bonn, Bonn, Germany
| |
Collapse
|
45
|
Francavilla R, Villette V, Luo X, Chamberland S, Muñoz-Pino E, Camiré O, Wagner K, Kis V, Somogyi P, Topolnik L. Connectivity and network state-dependent recruitment of long-range VIP-GABAergic neurons in the mouse hippocampus. Nat Commun 2018; 9:5043. [PMID: 30487571 PMCID: PMC6261953 DOI: 10.1038/s41467-018-07162-5] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Accepted: 10/18/2018] [Indexed: 11/21/2022] Open
Abstract
GABAergic interneurons in the hippocampus provide for local and long-distance coordination of neurons in functionally connected areas. Vasoactive intestinal peptide-expressing (VIP+) interneurons occupy a distinct niche in circuitry as many of them specialize in innervating GABAergic cells, thus providing network disinhibition. In the CA1 hippocampus, VIP+ interneuron-selective cells target local interneurons. Here, we discover a type of VIP+ neuron whose axon innervates CA1 and also projects to the subiculum (VIP-LRPs). VIP-LRPs show specific molecular properties and target interneurons within the CA1 area but both interneurons and pyramidal cells within subiculum. They are interconnected through gap junctions but demonstrate sparse spike coupling in vitro. In awake mice, VIP-LRPs decrease their activity during theta-run epochs and are more active during quiet wakefulness but not coupled to sharp-wave ripples. Together, the data provide evidence for VIP interneuron molecular diversity and functional specialization in controlling cell ensembles along the hippocampo-subicular axis.
Collapse
Affiliation(s)
- Ruggiero Francavilla
- Neuroscience Axis, CHU de Québec Research Center, Université Laval, Quebec, QC, G1V 4G2, Canada
- Department of Biochemistry, Microbiology and Bio-informatics, Université Laval, Quebec, QC, G1V 0A6, Canada
| | - Vincent Villette
- Neuroscience Axis, CHU de Québec Research Center, Université Laval, Quebec, QC, G1V 4G2, Canada
- Department of Biochemistry, Microbiology and Bio-informatics, Université Laval, Quebec, QC, G1V 0A6, Canada
| | - Xiao Luo
- Neuroscience Axis, CHU de Québec Research Center, Université Laval, Quebec, QC, G1V 4G2, Canada
- Department of Biochemistry, Microbiology and Bio-informatics, Université Laval, Quebec, QC, G1V 0A6, Canada
| | - Simon Chamberland
- Department of Biochemistry, Microbiology and Bio-informatics, Université Laval, Quebec, QC, G1V 0A6, Canada
| | - Einer Muñoz-Pino
- Neuroscience Axis, CHU de Québec Research Center, Université Laval, Quebec, QC, G1V 4G2, Canada
- Department of Biochemistry, Microbiology and Bio-informatics, Université Laval, Quebec, QC, G1V 0A6, Canada
| | - Olivier Camiré
- Neuroscience Axis, CHU de Québec Research Center, Université Laval, Quebec, QC, G1V 4G2, Canada
- Department of Biochemistry, Microbiology and Bio-informatics, Université Laval, Quebec, QC, G1V 0A6, Canada
| | - Kristina Wagner
- Department of Pharmacology, Oxford University, Oxford, OX1 3QT, UK
| | - Viktor Kis
- Department of Pharmacology, Oxford University, Oxford, OX1 3QT, UK
| | - Peter Somogyi
- Department of Pharmacology, Oxford University, Oxford, OX1 3QT, UK
| | - Lisa Topolnik
- Neuroscience Axis, CHU de Québec Research Center, Université Laval, Quebec, QC, G1V 4G2, Canada.
- Department of Biochemistry, Microbiology and Bio-informatics, Université Laval, Quebec, QC, G1V 0A6, Canada.
| |
Collapse
|
46
|
Wagner K, Imkamp F, Pires VP, Keller PM. Evaluation of Lightmix Mycoplasma macrolide assay for detection of macrolide-resistant Mycoplasma pneumoniae in pneumonia patients. Clin Microbiol Infect 2018; 25:383.e5-383.e7. [PMID: 30391582 DOI: 10.1016/j.cmi.2018.10.006] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2018] [Revised: 10/08/2018] [Accepted: 10/12/2018] [Indexed: 10/28/2022]
Abstract
OBJECTIVES Rapid detection of macrolide resistance-associated mutations in Mycoplasma pneumoniae is crucial for effective antimicrobial treatment. We evaluated the Lightmix Mycoplasma macrolide assay for the detection of point mutations at nucleotide positions 2063 and 2064 in the 23S ribosomal RNA (rRNA) gene of M. pneumoniae that confer macrolide resistance. METHODS Samples from 3438 patients with a respiratory tract infection were analysed by M. pneumoniae real-time PCR, and 208 (6%) of them were tested positive. In this retrospective study, 163 M. pneumoniae real-time PCR-positive samples were analysed by the Lightmix assay, and results were compared to targeted 23S rRNA sequencing. RESULTS Macrolide-resistant M. pneumoniae were found in 15 (9%) of 163 retrospectively analysed samples. The Lightmix assay showed a sensitivity of 100% (95% confidence interval, 78.2-100) and a specificity of 100% (95% confidence interval, 97.5-100) as the detected M. pneumoniae genotype (148 wild type and 15 non-wild type) was confirmed by 23S rRNA sequencing in all samples. CONCLUSIONS The Lightmix assay is an easy-to-use and accurate molecular test that allows rapid determination of macrolide resistance in M. pneumoniae.
Collapse
Affiliation(s)
- K Wagner
- Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
| | - F Imkamp
- Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
| | - V P Pires
- Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
| | - P M Keller
- Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland
| |
Collapse
|
47
|
Promislow S, Rizk H, Wagner K, Hindieh W, Messika-Zeitoun D, Beauchesne L, Burwash I. COMPARISON OF INFERIOR VENA CAVA ASSESSMENT BY 2-DIMENSIONAL AND M-MODE ECHOCARDIOGRAPHY FOR THE EVALUATION OF RIGHT ATRIAL PRESSURE. Can J Cardiol 2018. [DOI: 10.1016/j.cjca.2018.07.110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
48
|
Wagner K, Wong B, Byrne B, Sweeney H, Jacobsen L, Tirucherai G, Rabbia M, Dukart J, Kletz H, Krishnan M, Bechtold C. DMD CLINICAL THERAPIES I. Neuromuscul Disord 2018. [DOI: 10.1016/j.nmd.2018.06.151] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
49
|
Girardo S, Träber N, Wagner K, Cojoc G, Herold C, Goswami R, Schlüßler R, Abuhattum S, Taubenberger A, Reichel F, Mokbel D, Herbig M, Schürmann M, Müller P, Heida T, Jacobi A, Ulbricht E, Thiele J, Werner C, Guck J. Standardized microgel beads as elastic cell mechanical probes. J Mater Chem B 2018; 6:6245-6261. [PMID: 32254615 DOI: 10.1039/c8tb01421c] [Citation(s) in RCA: 55] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Cell mechanical measurements are gaining increasing interest in biological and biomedical studies. However, there are no standardized calibration particles available that permit the cross-comparison of different measurement techniques operating at different stresses and time-scales. Here we present the rational design, production, and comprehensive characterization of poly-acrylamide (PAAm) microgel beads mimicking size and overall mechanics of biological cells. We produced mono-disperse beads at rates of 20-60 kHz by means of a microfluidic droplet generator, where the pre-gel composition was adjusted to tune the beads' elasticity in the range of cell and tissue relevant mechanical properties. We verified bead homogeneity by optical diffraction tomography and Brillouin microscopy. Consistent elastic behavior of microgel beads at different shear rates was confirmed by AFM-enabled nanoindentation and real-time deformability cytometry (RT-DC). The remaining inherent variability in elastic modulus was rationalized using polymer theory and effectively reduced by sorting based on forward-scattering using conventional flow cytometry. Our results show that PAAm microgel beads can be standardized as mechanical probes, to serve not only for validation and calibration of cell mechanical measurements, but also as cell-scale stress sensors.
Collapse
Affiliation(s)
- S Girardo
- Biotechnology Center, Center for Molecular and Cellular Bioengineering, Technische Universität Dresden, Tatzberg 47/49, 01307 Dresden, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Gärtner A, Wagner K, Hölper S, Kunz K, Rodriguez MS, Müller S. Acetylation of SUMO2 at lysine 11 favors the formation of non-canonical SUMO chains. EMBO Rep 2018; 19:embr.201846117. [PMID: 30201799 DOI: 10.15252/embr.201846117] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2018] [Revised: 08/16/2018] [Accepted: 08/17/2018] [Indexed: 12/12/2022] Open
Abstract
Post-translational modifications by ubiquitin-related SUMO modifiers regulate cellular signaling networks and protein homeostasis. While SUMO1 is mainly conjugated to proteins as a monomer, SUMO2/3 can form polymeric chains. Poly-SUMOylation is best understood in the SUMO-targeted ubiquitin ligase (StUbL) pathway, where chains prime proteins for subsequent ubiquitylation by StUbLs. SUMO chains typically form in response to genotoxic or proteotoxic stress and are preferentially linked via lysine 11 of SUMO2/3. Here, we report that K11 of SUMO2/3 undergoes reversible acetylation with SIRT1 being the K11 deacetylase. In a purified in vitro system, acetylation of SUMO2/3 impairs chain formation and restricts chain length. In a cellular context, however, K11 acetyl-mimicking SUMO2 does not affect the StUbL pathway, indicating that in cells non-canonical chains are more prevalent. MS-based SUMO proteomics indeed identified non-canonical chain types under basal and stress conditions. Importantly, mimicking K11 acetylation alters chain architecture by favoring K5- and K35-linked chains, while inhibiting K7 and K21 linkages. These data provide insight into SUMO chain signaling and point to a role of K11 acetylation as a modulator of SUMO2/3 chains.
Collapse
Affiliation(s)
- Anne Gärtner
- Institute of Biochemistry II, Medical School, Goethe University, Frankfurt, Germany
| | - Kristina Wagner
- Institute of Biochemistry II, Medical School, Goethe University, Frankfurt, Germany
| | - Soraya Hölper
- Institute of Biochemistry II, Medical School, Goethe University, Frankfurt, Germany
| | - Kathrin Kunz
- Institute of Biochemistry II, Medical School, Goethe University, Frankfurt, Germany
| | - Manuel S Rodriguez
- Institut des Technologies Avancées en sciences du Vivant-UPS and IPBS-CNRS, Toulouse Cedex 1, France
| | - Stefan Müller
- Institute of Biochemistry II, Medical School, Goethe University, Frankfurt, Germany
| |
Collapse
|